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Abstract 
Hematopoietic stem cell transplantation (HCT) is the transplantation of stem cells or 
blood from a donor and an effective treatment for many hematologic malignancies. After an 
initially slow evolution, HCT has seen rapid expansion over the last two decades and major 
changes in technology use. HCT is a costly procedure ranked as one of the five most expensive 
medical procedures that generally exceed $140,000 for allogeneic (using stem cells from a donor) 
HCT and has a median length of stay of 35 days. HCT care provides an important opportunity to 
identify how center attributes can impact outcomes. Specifically, results can inform how payers, 
providers and policymakers can achieve high quality outcomes in the context of accreditation, the 
management of patient case mix and distance to facility. Using data from the Center for 
International Blood & Marrow Transplant Research (CIBMTR), a registry that collects transplant 
essential data (TED) data that includes disease type, age, sex, pre-transplant disease stage, date of 
diagnosis, graft type and cause of death. This research evaluates the current gaps in knowledge by 
1) evaluating the mechanism between patient case mix and overall HCT center quality (survival) 
2) identifying if centers of excellence and accreditation could explain differences in outcomes 
overall center quality and patient outcomes for complex HCT 3) understanding the impact of 
distance on overall survival and further evaluating the impact of distance on complex HLA 
mismatched patients. Overall, this research provides significant evidence for future 
recommendations surrounding the relative impact of risk stratification, center accreditation and 
distance on HCT survival.  
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Chapter 1: Specific Aims 
Hematopoietic stem cell transplantation (HCT) is the transplantation of stem cells 
or blood from a donor and an effective treatment for many hematologic malignancies. 
Each year, approximately 17,000 patients receive HCT in the U.S. This number has 
steadily increased since 2000, and there are no signs of this trend abating.1 More than 
fifty years have passed since the first reports of successful bone marrow transplants 
from human leukocyte antigen (HLA) identical siblings for patients with immune 
deficiency disorders. 2 After an initially slow evolution, HCT has seen rapid expansion 
over the last two decades and major changes in technology use. HCT is a costly 
procedure ranked as one of the five most expensive medical procedures that generally 
exceed $140,000 for allogeneic (using stem cells from a donor) transplantation and have 
a median length of stay of 35 days. 3 In 2005, underscoring the importance of quality 
improvement and efficiency for HCT, the Stem Cell Therapeutic and Research Act 
(SCTRA) was passed by the U.S. Congress. 4 The SCTRA legislated that outcome data 
be collected on all recipients of stem cell therapeutic products. As resources are limited 
and health expenditures continue to increase dramatically, reducing HCT costs and 
increasing HCT quality and effectiveness deserves critical examination.  HCTs are 
typically conducted in centers of excellence and the literature has shown that as patient 
complexity increases, transplant-related morbidity and mortality also increases but has 
paid little attention to specific center characteristics to broaden our understanding of this 
relationship.5-18 Identifying center focused pathways for improved survival and treatment 
is critical for increasing quality of care and reducing costs. There is wide variation in 
outcomes by center. To date, the literature lacks concensus on the driving force behind 
this center variation. 6 Current research evaluating the ability of patient complexity to 
significantly impact survival is limited both in the extent to which potential confounders 
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are addressed and in discussion of how other factors (such as transplant center 
characteristics and distance to facility) influence survival and complications. This gap in 
knowledge presents an opportunity to further evaluate the predictors of the performance 
of centers prepared to perform complex HCT. Moreover, the current research is limited 
in the extent to which transplant center factors drive the risk-survival relationship.19-20   
In order to further understand the relationship between HCT survival and center 
quality I will use the Center for International Blood & Marrow Transplant Research 
(CIBMTR) data, a registry that collects transplant essential data (TED) data that includes 
disease type, age, sex, pre-transplant disease stage, date of diagnosis, graft type and 
cause of death from HCT centers in the United States. If center factors such as center 
accreditation, center case mix and distance are the predominant forces that drive HCT 
center quality we should see a relationship between center characteristics and survival. 
Therefore, the specific aims of my proposed research are to: 
Specific Aims 
(1) Evaluate differences in outcomes among lower risk HCT patients by centers that 
transplant high risk patients versus centers that do not.  
 
(2) Determine whether there are differences in outcomes among HLA matched and 
mismatched HCT by centers that obtain the Foundation for the Accreditation of Cellular 
Therapy (FACT) and Blood and Marrow Transplant Clinical Trials Network (CTN) status.  
 
(3) Determine if the travel time to the nearest transplant center moderates the center 
quality relationship with HCT survival and post-transplant complications. 
 Understanding the mechanisms that influences HCT survival and lead to 
improved overall outcomes will be instrumental in the design of future quality 
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improvement programs for HCT. Identifying and understanding the best combined 
components that significantly improve cancer outcomes in the U.S. is imperative for the 
overall improvement of HCT care. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
Chapter 2: Statement of Purpose and Background 
Over the past several decades, the development of quality guidelines and 
recommendations for HCT center care has become a priority for payers, providers and 
policy makers. 21 With rising health care costs, the rapidly aging population and 
complexity of care the optimizing of care through identifying centers of excellence has 
become an area of substantial interest to policy makers as it identifies effective, 
appropriate and affordable therapeutic care. The Patient Protection and Affordable Care 
Act (ACA) was passed in March 2010 and the full implementations of the key elements 
of the reform strategy are scheduled for 2014. 22 The ACA has created an opportunity to 
advance delivery and payment system reform. A major component of the ACA 
emphasizes the improvement of quality as a means to reduce costs.  The ACA further 
expands the use of quality measures and metrics to identify centers that achieve high 
quality care and specifically rewards centers that achieve the highest levels of 
excellence. Identifying pathways for improved center quality has become an area of 
substantial interest to policy makers as it identifies specific factors that could be 
introduced to all centers to improve treatment, survival and long term outcomes. 
HCT care provides an important opportunity to identify centers of excellence and 
how quality outcomes can be achieved for complex, resource intensive specialty care. 
Over the last two decades, practice groups and accrediting bodies such as the 
Foundation for the Accreditation of Cellular Therapy (FACT) a non-profit entity co-
founded by the International Society for Cellular Therapy and the American Society of 
Blood and Marrow Transplantation in 1996 23 have published standards of excellence 
that are readily available to all centers. The guidelines are still widely recognized and 
utilized as standards of excellence set by clinical experts in the field of transplantation 
medicine, surgery, nursing and pharmacy. Payers and providers have encouraged HCT 
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quality improvement through the use and adoption of FACT guidelines as they are 
thought to be centers of excellence. Although many patient factors account for variation 
in outcomes there is no clear consensus opinion on the center level factors that can 
account for HCT center quality variation.    
From the perspective of policy makers and payers and in the context of rapidly 
rising health care costs, identifying centers that are most likely to provide effective and 
beneficial care remains an important goal. Cost effectiveness is especially important for 
HCT in light of a recent report from the Agency for Healthcare Research and Quality 
highlighted that despite being a relatively uncommon procedure, HCT was among the 
top ten procedures with the highest increase in hospital costs from 2004 to 2007 in the 
United States in which the total national costs of HCT hospitalization increased from 
$694 million to $1.3 billion over this time period. 24 Therefore, understanding where to 
focus quality guidelines and how to identify the components of HCT centers of 
excellence that are most effective in instigating quality for both complex and lower risk 
patients remains important for minimizing health care costs and optimizing outcomes.  
In order to further understand the relationship between complex, resource 
intensive specialty HCT care and outcomes, several studies have indicated several 
patient characteristics that are clinically important to the long term survival of HCT 
recipients. To determine patient risk and complexity, four characteristics have been 
consistently reported across studies to be associated with survival following HCT: age at 
transplant, HLA match status, Karnofsky performance score and comorbidities.5-18Little 
attention has been paid to overall patient complexity and center characteristics over 
time. Further understanding the mechanism between HCT center survival and 
complexity will help focus future HCT quality guidelines. If there is indeed no 
advantageous “spillover” impact that occurs for the low risk, less complex HCT patient 
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population as a result of having HCT in a center that treats patients with higher risk, 
payers, patients and providers might restrict travel to centers of excellence. Furthermore, 
the case mix of a center should not necessarily be viewed as a sign of excellence by 
payers, patients, providers, and HCT center administrators. If complex patient volume is 
indeed an indicator of center excellence and elevates quality outcomes for all patients, 
all centers should increase patient complexity to achieve excellence and improve overall 
quality.  
The HCT literature that focuses on centers of excellence and the management of 
patient complexity is limited. Although several transplant center characteristics have 
been associated with increased survival such as workforce and volume, no studies have 
systematically evaluated differences in centers’ characteristics and accreditation status 
and the resulting impact on outcomes. Majhail et al. found that practice variation, such 
as physician staffing, transplant capacity, clinician approach to transplantation for 
hematologic disorders and choice of graft source, can impact the quality of care for 
transplant recipients. 19 Using Center for International Blood & Marrow Transplant 
Research data from 1998-2000, Loberiza et al. found significant survival differences for 
patients receiving allogeneic HCT in centers with one or more favorable center related 
factors such as lower physician caseload, contact for afterhours call and medical school 
affiliation. 6 However, Loberiza did not find an association between factors that might be 
expected to correlate with increased levels of survival such as FACT accreditation 
(yes/no) and NCICCC designation.  
In order to further understand the impact of distance and geographical location 
on HCT outcomes, several studies have examined rural/urban distinctions and distance 
to HCT for single center analyses. Although there is an extensive literature that observes 
distinct disparities in cancer outcomes and survival based on the distance to the 
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treatment center25-32, few have focused on nationwide U.S. HCT. Previous findings of 
Abou-Nassar et al. showed inferior outcomes for patients that resided 160-360 minutes 
driving time from the Dana-Farber/Brigham and Women’s Cancer Center. 33 In a study at 
the University of Nebraska Medical Center between 1983 and 2004, primary area of 
residence was used to classify patients as either rural or urban. 34 Results were mixed. 
Among the autologous HCT patients, those from rural areas were found to have a higher 
mortality versus patients from urban areas but this difference was not evident for 
patients undergoing allogeneic HCT. A registry study from Canada found that there were 
no significant survival differences between urban and rural patients undergoing 
autologous or allogeneic HCT. 35 
Overall, the proposed research will evaluate the current gaps in the knowledge 
surrounding the impact of centers of excellence and distance to center for HCT care by 
1) Evaluating the mechanism between patient case mix and overall HCT center quality 
(survival)  2) Identifying if centers of excellence could explain differences in outcomes 
and further evaluating the mechanism between HCT center accreditation and overall 
center quality and patient outcomes for complex HCT 3) Understanding the impact of 
distance on overall survival and further evaluating the impact of distance on complex 
HLA mismatched patients. The current lack of consensus on where to focus HCT quality 
improvement efforts suggests that the proposed research will provide timely and 
significant evidence for future recommendations.  
Relationship between Patient Characteristics and HCT Outcomes 
The literature indicates several patient characteristics are clinically important to 
the long term survival of HCT recipients. To determine patient risk, four characteristics 
have been consistently reported across studies to be associated with survival following 
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HCT: age at transplant, HLA match status, Karnofsky performance score and 
comorbidities.5-18  
Age, Karnofsky Performance Score and Coexisting Disease at Transplant 
The literature has shown that the median age of transplanted patients has 
increased continuously over the past few decades. While the upper age limit for HCT for 
many years was 50 or 55 years, recent reports include patients in their 70s. The Center 
for International Blood and Marrow Transplantation Research (CIBMTR) database 
shows a median patient age of 25 years in the 1980s, 39 in the 1990s, and 46 over the 
past decade. From 2002 to 2009, 44% of patients were older than 50, and 20% older 
than 60 years. 36 Transplant recipients over the age of 40 were considered to be higher 
risk than their younger counterparts. 37Although older age is considered to be a higher 
risk indicator for HCT, research by McClune et al. showed that there is only a limited 
effect of age on outcomes of reduced-intensity hematopoietic cell transplantation for 
older patients with acute myeloid leukemia in first complete remission or with 
myelodysplastic syndrome. 37 They conclude that age over 40 alone should not be 
considered a contraindication to HCT. 
The Karnofsky performance status is used to determine the functional status of a 
recipient and can range from 0-100. 38 A Karnofsky performance score of 90-100 
categorizes patients with the ability to carry on normal activity and no special care is 
needed (see appendix for a full list of Karnofsky performance scoring). In a single center 
Canadian study, the Karnofsky performance score was determined to be an independent 
indicator of survival.  Karnofsky performance status was found to be a useful in 
predicting overall survival and in assisting treatment decisions. 39 Additionally, Sorror et 
al. found that coexisting disease and Karnofsky performance status assess different 
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levels of medical health status and that merging the information attained by the 2 scoring 
systems refined the outcome predictions for patients given nonmyeloablative HCT.13 
Coexisting disease is another important predictor of HCT outcomes and 
measurement of pre-transplant risk and complexity. The literature has consistently 
shown that coexisting disease adversely impacts outcomes.  In addition to using 
coexisting disease as a binary variable (yes/no), coexisting disease HCT index scores 
have been developed in order to more accurately capture comorbidity. Sorror et al. 
modified the established and more broadly applicable HCT index score by incorporating 
additional parameters with greater relevance in HCT and by assigning scores (1, 2, or 3) 
with better discriminating power to individual parameters. 11 The HCT-CI strictly 
considers only pre-transplantation patient characteristics, in particular cardiovascular, 
gastrointestinal, hepatic, and renal dysfunction along with antecedent solid cancer. 
Numerous reports have shown increased mortality and lower survival with increasing 
HCT-CI scores. Patients with scores of 3 or higher generally had significantly inferior 
survival, often half the probability of patients without comorbidities. 11-13  
Although the above mentioned studies that have used age, Karnofsky 
performance score and coexisting disease at transplant have all found these measures 
useful in assessing survival probability and post HCT outcomes at the patient level, few 
have used these measures to assess and stratify overall center risk. In addition to age, 
Karnofsky performance score and coexisting disease, HLA match status is also 
considered an important predictor of HCT survival.  
HLA Match Status  
Allogeneic hematopoietic cell transplantation (HCT) is a complex treatment for 
several hematological disease groups and involves the infusion of donor hematopoietic 
stem cells into a recipient. In the past several decades, human leukocyte antigen (HLA) 
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matching capabilities and refined methodology has buttressed clinical abilities to 
increase the successful performance of HCT. For example, donor and recipient HLA 
matches can be made on an 8 of 8 (match) or 7/8 (mismatched) HLA level for unrelated 
donor HCT. A 6/8 or lower donor recipient match is generally considered unacceptable 
for successful HCT.40 
The search for a donor and recipient HLA matches begins with the patient’s 
siblings who have the same parents as the patient. If a sibling is not a perfect match (8/8 
loci are matched), the search moves to other immediate family members and possibly 
unrelated donors creating four total categories; HLA matched related, HLA mismatched 
related, HLA matched unrelated and HLA mismatched unrelated transplants.15, 41  
Finding suitable related or unrelated donors has increasingly become more common in 
the last decade. It is widely accepted that match quality is an essential component of 
higher survival rates and improved long term outcomes among HCT recipients. 15-16, 40-42 
Clinical best practice dictates that whenever possible, HLA matched donors are 
preferable in regulating responses between donor and recipient, reducing the risk of 
post-transplant complications and infections and improving the chances for long term 
survival. 15-16, 40-42  
A matched transplant offers a greater chance of eradicating malignancy. 
Allogeneic HCT also confers a higher risk of transplant-related mortality due to slower 
hematopoietic and immunologic recovery and graft-versus-host disease (GvHD). 
Typically, a matched sibling donor is available for only 20-30 percent of the patients in 
need of a transplant. 40 The remainder of the recipients in need of transplants must rely 
on an unrelated donor bank population. The ideal unrelated donor for HCT has alleles 
matched at the HLA-A, -B, -C and DRB1 level. Under the assumption that a patient’s 
condition is stable a patient must decide if the benefits of waiting for a more suitable 
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match to be recruited outweigh the risks of waiting when no suitable donor is imminently 
available.  
The literature has shown that high resolution matching is a necessary component 
for survival of HCT. 15-16, 40-42 However, this does not imply that the availability of partially 
HLA matched donors is a contraindication to transplantation. The National Marrow 
Donor Program HLA-Matching guidelines for unrelated marrow transplants focus on 
three large contemporary studies that evaluated most of the HLA loci by using DNA 
testing to resolve alleles. The guidelines focused on survival as opposed to other 
outcomes such as engraftment and GvHD. Table 1 identifies the positions of the three 
sets of studies evaluating the relationship between HLA-matching levels and survival.  
The data sources for the three studies are (1) The Japanese Marrow Donor Program16-17 
(2) Fred Hutchinson Cancer Research Center (FHCRC) 15, 41  (3) The National Marrow 
Donor Program.42 These three sets of studies differ in their designs and conclusions. 
However, they all suggest that matching for HLA-A, -B, -C and DRB1 are integral for 
survival. This group of literature also emphasizes that matching at the allele, high-
resolution levels, provides a superior benefit to the recipient. In contrast, matching at the 
antigen level, information available through serological or low level molecular typing 
provides a less superior match. Overall, this set of literature agrees that the paradigmatic 
match quality level is the donor whose alleles match the recipient at HLA-A, -B, -C and 
DRB1. There is currently insufficient evidence for matching at HLA-DQ, -DP levels. The 
differences amongst the studies are attributed to several factors that include the concern 
of generalizability of the Japanese studies and immunological factors that vary across 
racial groups that could influence the relationship between HLA matching and 
transplantation outcomes.  Results from Petersdorf and Flomenberg indicate that 
survival worsened with an increase in allelic donor mismatch. 15, 41-42   Additionally, 
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differing sample sizes amongst the studies limited how mismatches were classified 
across multiple loci and the 3 studies collapsed the loci differently. Although 
methodologies are variable between the three groups of studies, each of the studies 
demonstrates that outcomes can be improved by matching strategies and HLA matching 
at higher levels.43 
Overall, the four critical components of predicting HCT survival that have been 
consistently reported across studies to be associated with patient risk and assessing 
survival probability and post HCT outcomes at the patient level following HCT are age at 
transplant, HLA match status, Karnofsky performance score and comorbidities.5-
18Although the above mentioned literature has found utility in using these characteristics 
to stratify patient risk few have used these measures to assess and stratify overall center 
risk.  
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Table 1: Studies Evaluating the Association between Human Leukocyte Antigen (HLA) Matching and Survival 
 
Population Eligible Diagnosis Study Design Comparison Outcomes Timing Study 
 
1249 
patients 
Data 
source: 
(FHCRC) 
Treatment for 
leukemia or 
myelodysplastic 
syndrome (MDS) 
Retrospective 
Cohort 
Matched, one mismatch, two 
or more mismatches groups 
compared on survival. 
Single mismatches in low risk 
patients were associated with a 
statistically significant risk with 
no difference on match for high 
risk patients. 
1985-2003 Petersdorf15, 41  
 
 
 
 
 
1298 
patients 
 
 
 
 
 
AML, ALL, CML, 
MDS, SAA, others 
Retrospective 
Cohort 
Collapsed mismatches on A 
and B together and on DR 
and DQ together to get a 
larger sample size for 
detecting differences among 
groups. 
Identified the combined A/B 
groups as having a stronger 
effect on survival than the other 
loci 
1993-1998 Morishima16  
 
 
 
 
 
440 
patients 
 
 
 
80% of the 
population had 
leukemia and the 
remaining 20% had 
a diagnosis of 
lymphoma, marrow 
failure or a 
congenital disorder. 
 
 
 
 
Retrospective 
Cohort 
 
 
 
Donor mismatching was 
compared. For each donor-
recipient pair the. Donors 
were classified as matched, 
mismatched or no match. 
 
 
 
 
Mismatching of HLA-A but not 
HLA-C alleles was an 
independent risk factor of 
survival (p<.001). DRB-1 
showed no effect. (DR+DQ 
combined) 
 
 
 
 
 
 
 
 
Retrospect
ive DNA 
typing 
 
 
 
 
Sasazuki17 
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Table 1 
Continued 
Eligible Diagnosis Study Design Comparison Outcomes Timing Study Population 
423 
patients 
CML, AML, ALL, 
other malignant, 
nonmalignant 
Retrospective 
Cohort 
Of the 423 pairs, 282 pairs 
(67%) were matched for 5 
classic HLA loci (HLA-A, -B, -
C, -DRB1, -DQB1; ie, 10 of 
10 matched) and 141 were 
mismatched. Of the 141 
pairs, 111 were class I 
mismatched only, 19 were 
class II (DRB1, DQB1) 
mismatched only, and 11 
were mismatched at class I 
and class II 
Results indicate the presence of 
DPB1 allele incompatibility 
resulted in significant 
differences in the incidence of 
GvHD and disease relapse. 
1996-2003 Shaw44 
 
 
3857 
patients 
 
 
ALL/AML/ CML/MDS 
 
Retrospective 
Cohort 
 
8/8,7/8,6/8,5/8. Mismatches 
compared at specific loci 
Adverse effects of either allele 
or antigen mismatching on 
outcomes with 9-10% lower 1 
year survival for each additional 
mismatch. 6-7/8 v 8/8 
 
 
1983-2003 
Lee18 
 
 
1874 
patients 
Data 
source: 
National 
Marrow 
Donor 
Program) 
CML/AML/ALL/nonm
alignant disorders 
 
 
Retrospective 
Cohort 
Two levels of DNA based 
HLA matching were 
considered in the analyses-
High resolution and low 
resolution for each locus-
HLA/B/C/DRB1. 
Single mismatches at these loci 
were associated with significant 
decrements in survival, and the 
presence of multiple 
mismatches was even worse. 
 
 
1988-1996 
Flomenberg42 
14,797 
unrelated 
patient 
donors 
CML/ MDS/ NHL/HL 
Myeloma/SAA/Inheri
ted abnormalities of 
erythrocytes/SCID 
and other immune 
disorders/inherited 
disorder of 
metabolism/ 
histolytic 
disorders/Other 
malignancies 
Retrospective 
Cohort 
Disease status at transplant 
and survival after URD HCT 
by MLA match classification. 
Well matched/ partially 
matched/mismatched 
grouped into 21 possible 
match categories. 
URD HCT 83% had high 
resolution typing of all 4 loci-of 
those, 65% were well matched, 
26% partially matched and 6% 
mismatched. Earlier clinical 
reports may have obscured 
differences in outcomes that 
might have been attributable to 
incomplete HLA matching. 
1665-2006 Weisdorf45 
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Potential Confounders in the HLA Match Quality-Survival Relationship 
Patient Factors 
The observational studies reviewed in Table 1 examine the relationship between 
HLA match quality and survival and adjust for differing combinations of patient 
characteristics and hospital factors. The literature incorporates these factors as they 
might influence the relationship between match quality and outcomes. The literature 
often includes and adjusts patient factors such as patient age, gender, race, extent of 
disease, and severity (Table 2).  Current literature has evaluated HCT access by gender, 
age, race/ethnicity, insurance coverage, disease type and education. For example, 
Mehta et al. estimated the ratio of HCT transplantations for male and female allogeneic 
patients versus disease incidence and found no association between gender and the 
rates of HCT for individuals with AML and CML. 46 Hwang et al. evaluated Medicare 
beneficiaries in Texas and found that elderly women were significantly less likely to 
undergo HCT than elderly men.9 Hwang also evaluated insurance status and did not find 
a significant association between HCT and ethnicity or insurance coverage. Mitchell et 
al. found substantial variation for leukemia and lymphoma patients in access to HCT.47 
This difference was particularly significant amongst Black patients, those enrolled in 
HMOs, Medicaid patients and self-pay HCT recipients. The current HLA match quality 
literature has not fully evaluated and included socioeconomic status, transplant center 
characteristics or other factors that might influence survival in their survival models. As a 
result, these studies may not fully capture the true relationship between center 
characteristics, patient complexity and survival. 
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Table 2: HLA Match Quality-Survival Studies- Patient and Center Characteristic Confounders Included 
Study Age Gender Co- 
morbidity 
Race & 
Ethnicity 
Socio-
economic 
status 
Transplant 
Center 
Characteristics  
Distance to 
Transplant 
Center  
Insurance 
Petersdorf 
    X X X X 
Morishima 
   X X X X X 
Sasazuki 
   X X X X X 
Shaw 
    X X X X 
Lee 
    X X X X 
Flomenberg 
    X X X X 
Weisdorf 
    X X X X 
 
 
Relationship between Center Case Mix and HCT Outcomes and Survival 
As discussed above, there is a well-documented body of HCT literature that 
indicates certain patient characteristics such as HLA matching, co-morbidities, age and 
Karnofsky performance score are determinants of a patient’s pre-transplant risk level 
and survival rates.5-18 The literature has not used this patient stratification to stratify 
centers and determine the impact of risk management on overall center outcomes. 
There are several ways that patient case mix and risk can impact overall center 
performance. Variation in HCT patient characteristics in centers that treat higher risk 
patients could deplete resources for lower risk patients. Alternatively, the challenge of 
successfully managing high risk patients could benefit lower risk patients thereby 
increasing quality and lowering the procedural mortality for all patients.  
Relationship between Center Volume and HCT Outcomes and Survival 
 There is a large literature that documents a positive correlation between hospital 
volume and good outcomes. 48-59 Typically, morbidity and mortality is found to be lowest 
in centers that perform the most of any given procedure. These results have been shown 
for multiple conditions, procedures and environments including cancer. 60-61 There are 
almost always numerous low-volume providers with average or exceptional outcomes, 
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although these outcomes are not always reliable estimates of true performance because 
they are based on small sample sizes. There are two ways in which volume can be 
thought to impact outcomes. The “learning by doing” hypothesis argues that large 
centers or hospitals are more apt to provide higher quality care which thus improves 
overall outcomes. Alternatively, hospitals that offer superior quality care attract higher 
demand for services and thus have higher volume levels. In other words, high volume 
centers are rewarded based on perceived quality or expertise. The direction of this 
volume relationship is important. If volume per se is the important parameter, one can 
make a strong case for restricting transplants to large centers. If, on the other hand, 
volume is a surrogate for other factors that are more common in large versus small 
centers, but which could be introduced into small centers, the appropriate course of 
action would be to set standards for these factors to be adhered to by large and small 
centers. For instance, if studies substantiate that patient complexity and accreditation 
impacts survival in the HCT setting, then it may be possible for small centers to optimize 
other operational and organizational management features to ensure good outcomes, 
rather than attempt to increase procedure volume. 
Center Accreditation Status and HCT Survival 
Certifying and accrediting centers of excellence are not novel approaches to 
oversee and underscore standards of excellence and health care quality and outcomes. 
There is a broad literature exploring whether there are differences in process and 
outcomes at academic health centers, accredited centers of excellence, teaching 
hospitals and the National Cancer Institute’s Comprehensive Cancer Centers (NCICCC). 
62-72 Results have been mixed. For example, using the national Medicare database, 
Birkmeyer et al. conducted an analysis of 51 NCICCC and six cancer procedures, 
cystectomy, colectomy, pulmonary resection, pancreatic resection, gastrectomy, and 
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esophagectomy cancer.62 Although Birkmeyer did not fully account for selection bias, 
she found that NCI designated cancer centers had lower surgical mortality rates than 
those treated at comparably high-volume hospitals, but had similar long-term survival 
rates. 62 Meguid et al. found that in-hospital outcomes are superior for patients 
undergoing lung cancer resections at teaching hospitals, with results prominent at all but 
the highest volume institutions.63 
Another body of literature that analyzed either process measures of care or that 
assessed risk-adjusted mortality rates found differences in quality between major 
teaching hospitals and nonteaching hospitals across several cancer groups.64-68These 
differences have been reported in combined analyses of multiple conditions but have not 
always been consistent in finding significant results and rarely do these analyses control 
for center volume. 
The HCT literature that focuses on center characteristics and FACT certification 
is limited. Several transplant center characteristics have been associated with increased 
survival. Majhail et al. found that practice variation, such as physician workforce, 
transplant capacity, clinician approach to transplantation for hematologic disorders and 
choice of graft source can impact the quality of care for transplant recipients. 19 Using 
Center for International Blood & Marrow Transplant Research data from 1998-2000, 
Loberiza et al. found significant survival differences for patients receiving allogeneic HCT 
in centers with one or more favorable center related factors such as physician caseload, 
contact for afterhours call and medical school affiliation.20 However, Loberiza did not find 
an association between factors that might be expected to correlate with increased levels 
of survival such as FACT accreditation (yes/no) and NCICCC designation.  
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Despite numerous studies that have evaluated the FACT accreditation status, the 
literature has not stratified centers by patient risk to determine differences. Furthermore, 
since FACT’s inception, nearly two decades ago, FACT accreditation has become 
ubiquitous among HCT centers and it is possible that HCT techniques have consistently 
improved across all centers irrespective of accreditation status.  
Relationship between Distance to Facility and HCT Survival and Post-Transplant 
Complications 
Since distance is an important determinant of the location of treatment for 
emergent conditions, increased travel times may increase the likelihood of an adverse 
health outcome for such conditions. Acute myocardial infarction (AMI) and acute stroke 
are two common diagnoses where time to treat is an important determinant of health 
outcomes. 73-76 For HCT distance to facility is important for expediting the process that 
leads to the donor recipient match, diagnostic screening and for post-transplant care.  As 
explained above, the complexity of HCT requires patients to remain in close proximity to 
the transplant center post-transplant. Patients that travel long distances or that opt to 
receive post-transplant care from physicians in non-urban locations may receive 
suboptimal care. Physicians located in non-urban areas that are poorly trained for post-
transplant complexity may provide inadequate treatment and be bereft of advanced 
techniques necessary for HCT patients.   
The General Accounting Office estimates that in the United States, only one third 
of patients who need transplants from unrelated donors have preliminary searches 
requested from the National Marrow Donor Registry.77 For some conditions the 
importance of travel time likely outweighs the benefits of receiving care at a higher 
quality facility. AMI and acute stroke are two of our study conditions that likely fall into 
that category. However, for conditions that are less time sensitive the benefits of receive 
care at higher quality facilities likely outweighs the disadvantages of increased travel 
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times in impacting health outcomes. 32 Congestive heart failure and hip fracture are two 
conditions that may fall into that category. Finally, for some conditions like pneumonia, 
there is evidence that smaller hospitals provide higher quality care than their larger 
counterparts. 25 HCT remains a risky procedure with many possible complications; it has 
traditionally been reserved for patients with life-threatening diseases. Distance to facility 
is of particular importance for both pre and post HCT care.   
Although HCT now save thousands of lives each year, 70% of those needing a 
HCT using donor marrow are unable to have one because a suitable bone marrow donor 
cannot be found. 23 This barrier to care is for potential recipients that are already in the 
registry and is not a product of distance. However, HCT patients that are in the registry 
may potentially travel further to go to receive potentially inferior care. Ultimately, access 
to transplants and geographic barriers to HCT contribute to a patient’s decision to be 
treated. There are certainly socioeconomic and health insurance factors that contribute 
to the eligible transplant recipient (these variables are not collected in the registry). 
However, often transplantation is considered only after transplantation is no longer a 
viable and safe alternative. Distance delays diagnosis and potentially terminates any 
necessary care before being started. For a transplant recipient patient the potential 
benefit of transplantation often occurs if the patient resides in close proximity to the 
transplant center. Although there is an extensive literature that observes distinct 
disparities in cancer outcomes and survival based on the distance to the treatment 
center26-32, few have focused on nationwide U.S. HCT. Previous findings of Abou-Nassar 
et al. showed inferior outcomes for patients that resided 160-360 minutes driving time 
from the Dana-Farber/Brigham and Women’s Cancer Center. 33 In a study at the 
University of Nebraska Medical Center between 1983 and 2004, primary area of 
residence was used to classify patients as either rural or urban.  Results were mixed. 
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Among the autologous HCT patients, those from rural areas were found to have a higher 
mortality versus patients from urban areas but this difference was not evident for 
patients undergoing allogeneic HCT. 34A registry study from Canada found that there 
were no significant survival differences between urban and rural patients undergoing 
autologous or allogeneic HCT. 35 
Limitations to Current Research 
The current literature that evaluates HCT does little to incorporate center 
attributes to their exploration of HCT variation. The gap in knowledge presents an 
opportunity to further evaluate predictors of patient and center variation. Further, current 
research is limited in the extent to which center factors drive survival and post-transplant 
outcomes for HCT patients. Studies fully incorporating these confounding factors may 
demonstrate that the survival relationship is more likely attributable to HCT center quality 
and centers of excellence.  
Conceptual Model 
As seen in the literature review, three main groups of factors can influence the 
survival of HCT patients: patient, provider and transplant center characteristics (Figure 1: 
Conceptual Model). Although the transplant physician is ultimately responsible for the 
HCT treatment and success to the transplant, multiple patient characteristics can 
influence the HCT. In addition to specific patient biological characteristics, patient factors 
such as age, gender and extent of comorbidities can all impact survival. In addition to 
patient factors, provider characteristics and factors significantly influence technique, 
knowledge and experience, which all differentially influence the likelihood of superior 
HCT outcomes. Specifically, a surgeon’s specialty, professional certification, years in 
practice and HCT volume all influence the ability to treat high risk HCT recipients. 
Although a HCT physician’s ability to treat a lower risk transplant recipient should be 
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independent of patient characteristics, disease characteristics or unmeasured biological 
changes may influence a provider’s ability to achieve favorable outcomes. 
 The willingness to care for high risk HCT recipients can also be significantly 
influenced by hospital characteristics, which can influence the culture or expectations of 
transplant center superiority and the overall perception of quality. These factors include 
those characteristics that are known to influence other cancer quality outcomes such as 
survival. Such characteristics include hospital volume for HCT procedures, type of 
ownership, teaching status and NCI/FACT designation.  
 Receipt of adequate post-transplant care, while also influenced by patient, 
provider and hospital characteristics, is modified by initial HLA match quality. In other 
words, individuals that are low risk HCT recipients are more likely to receive quality care 
along the HCT continuum. Once they enter a high quality system, they continue to 
receive appropriate therapy in a timely manner. Using a transplant recipient risk level as 
an initial surrogate for center risk levels-we are able to ascertain if transplant centers are 
able to sustain high levels of quality as risk tolerance evolves. The current literature has 
not yet explored the influence of patient and transplant center characteristics on the HCT 
continuum for various risk levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23 
 
Figure 1: Conceptual Model of factors that influence HCT survival 
 
 
 
Contribution of the Dissertation to Previous Work 
Understanding the mechanism that influences HCT survival will be instrumental 
in the design of future quality improvement programs that focus on implementing more 
transparent HCT results. While center characteristics, HCT match quality, patient 
complexity, center case mix and travel distance for HCT may not drive improved 
survival, identifying and understanding the best combined components that significantly 
improve cancer outcomes in the U.S. is imperative for the overall improvement of HCT 
care. 
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Chapter 3: Do Hematopoietic Cell Transplantation Centers that Perform Higher 
Risk Hematopoietic Cell Transplantation have Superior Survival Outcomes for 
Lower Risk Transplants? 
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Background: Allogeneic hematopoietic cell transplantation (HCT) is the transplantation 
of stem cells from a donor and an effective treatment for many hematologic 
malignancies. Although major progress has been made in pre-transplant patient risk 
assessment, the research has typically used risk scores to measure differences in HCT 
survival outcomes without identifying or aggregating results to the transplant center at 
the U.S. national level. Given the lack of a center based approach in the literature we 
sought to compare allogeneic HCT survival outcomes and hazard of death amongst U.S. 
centers that treat higher risk patients versus lower risk centers that do not.  
Methods: To further evaluate the association between pre-transplant risk and HCT 
survival by transplant center, we utilized January 1, 2008-December 31, 2010 Center for 
International Blood & Marrow Transplant Research (CIBMTR) data. We categorized 
patients into 4 risk categories (RC) that align with factors shown to be associated with 
HCT survival: (a) age, (b) Karnofsky performance scoring, (c) co-existing disease and 
(d) the human leukocyte antigen (HLA) match status of transplant donors. We stratified 
centers into those that conduct high pre-transplant risk HCT and examined the 
association between risk category score and hazard of death using Cox proportional 
hazard modeling.  
Results: There were 12,264 HCT recipients at 147 transplant centers from 2008-2010 in 
the cohort. Of the 147 centers, 74 centers performed HCT for patients ranging from the 
lowest risk category (RC=0) to the highest level category (RC=4) and 73 centers that 
performed only lower risk HCT (RC=0-3). With the exception of the lowest risk category 
patients (RC=0), we observed an increase in HCT in all risk categories from 2008-2010. 
After adjusting for race, sex, year of transplant, HHS region and broad disease 
categories, we found that our high pre-transplant risk categories were all significantly 
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associated with higher relative hazard of death versus lower pre-transplant risk groups. 
Controlling for all other factors, we found that lower risk patients that underwent 
transplants in lower or higher risk centers had similar relative hazard of death.  
Conclusions: Research has previously shown that providers with more experience 
(‘learning by doing’) produce better outcomes. Although the surgical literature has shown 
a direct relationship between procedure volume and survival 19-25, our results point to 
the fact that higher procedure volume, and a willingness to take on riskier transplants 
does not directly translate into improved outcomes for all other patients. Low risk 
patients had similar survival outcomes irrespective of whether they are transplanted at 
higher or lower risk centers. There was no apparent benefit or harm for lower risk 
patients receiving HCT at higher risk centers. Patient and payer policy implications could 
include initiatives that reduce travel for low risk patients. Similarly, HCT center 
administrators and providers that manage higher risk patients need not expect benefits 
in survival for lower risk patients.  The number of HCTs performed has markedly 
increased in the past several decades. While centers continue to explore and expand 
the possibilities of HCT for higher risk transplants there should be sustained emphasis 
on maintaining proficiency and superior outcomes for lower risk recipients.  
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Background 
Hematopoietic cell transplantation (HCT) is a complex treatment procedure for various 
hematologic malignancies and other conditions that are often otherwise are incurable. 
Each year, approximately 17,000 patients receive HCT in the United States. This 
number has been steadily increasing since 2000. 1 HCT is performed using 
hematopoietic progenitor cells from the patient (autologous transplant) or a human 
leukocyte antigen (HLA) matched related or unrelated donor (allogeneic transplant) to 
reestablish function in patients with damaged or defective bone marrow or immune 
systems. Advances in transplantation over the last four decades have resulted in an 
increasing number of centers that are more willing to perform more complex and higher 
risk transplants. While mortality is a common and useful measure of transplant center 
quality, comparing outcomes between centers is challenging if estimates do not take 
differences in transplant populations into account. 78-79 For instance, centers that 
transplant a relatively larger percentage of high risk patients with an intrinsically higher 
risk of mortality may be potentially perceived as poor performers in comparison to 
centers that transplant a lower percentage of such patients.  
There are several ways that patient case mix and risk can impact overall center 
performance. Variation in HCT patient characteristics in centers that treat higher risk 
patients could deplete resources for lower risk patients. For example, a common 
argument made for case mix adjustment is that a centers’ overall performance should be 
adjusted for underlying differences in patient population characteristics that directly and 
adversely impacts performance. 80-82  Alternatively, the challenge of successfully 
managing high risk patients could benefit lower risk patients thereby increasing quality 
and lowering the procedural mortality for all patients. For example, there is a literature 
that supports the hypothesis that when complex surgical oncologic procedures are 
 28 
 
provided by surgical teams in hospitals with specialty expertise, overall mortality rates 
are lower. There is a well-documented body of HCT literature that indicates certain 
patient characteristics such as HLA matching, co-morbidities, age and Karnofsky 
performance score are determinants of a patient’s pre-transplant risk level and survival 
rates.5-18 
In this paper we explore the effects on survival for lower risk HCT patients being 
transplanted at HCT centers that do or do not perform high risk transplants.  We also 
explore the effect of HCT risk management on centers. Specifically, we focus on 
potential spillover effects and benefits of higher risk HCT performance on the low risk 
patient population of centers.  Under the Stem Cell Therapeutic and Research Act 
(SCTRA) of 2005 there has been a strengthened clinical and health policy emphasis for 
increased transplant survival outcomes transparency, including the dissemination of 
research and the effectiveness of transplant program operations. Our work focuses on 
determining a center’s deftness to successfully transplant the full spectrum of recipients 
regardless of the levels of patient complexity. We sought to evaluate differences in 
outcomes among lower risk HCT patients by risk stratifying centers that transplant high 
risk patients versus centers that do not perform high risk HCT.  
Methods 
Data Source 
The Center for International Blood & Marrow Transplant Research (CIBMTR) is a 
research affiliation of the International Bone Marrow Transplant Registry, Autologous 
Blood and Marrow Transplant Registry, and National Marrow Donor Program (NMDP) 
that was established in 2004. CIBMTR is comprised of a voluntary working group of 
more than 450 transplantation centers worldwide that contribute detailed data on 
consecutive HCT to a Statistical Center at the Medical College of Wisconsin in 
Milwaukee, WI and the NMDP Coordinating Center in Minneapolis, MN. In addition, the 
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CIBMTR holds the contract for the Stem Cell Therapeutic Outcomes Database part of 
the CW Bill Young Transplantation Program from the Human Resources and Services 
Administration. As part of this Program, all transplant centers in the US are mandated to 
report clinical outcomes data for allogeneic HCT to the CIBMTR. All CIBMTR teams 
contribute registration data (also called transplant essential data (TED)). These data 
include disease type, age, sex, pre-transplant disease stage, date of diagnosis, graft 
type, conditioning regimen, post-transplant disease progression and survival, 
development of a new malignancy, and cause of death. TED level data are collected 
before transplant, 100 days and 6 months after transplant, and annually thereafter or 
until death. We obtained a de-identified dataset from CIBTMR. Our study was deemed 
exempt from review by the Human Subjects Committee of the University of Minnesota’s 
Institutional Review Board.  
Patients 
We included transplant recipients 18 years or older who received transplants 
between January 1, 2008, through December 31, 2010 and were reported to the 
CIBTMR. We included patients who received peripheral blood stem cells or bone 
marrow graft from HLA-matched or mismatched, related or unrelated donors.  All 
diagnoses were included. We excluded patients missing any of the four risk category 
criteria (N=406 patients, see below for risk category derivation) and centers that reported 
only one transplant from 2008-2010 (N=15 Centers).  
Derivation and Definition of the Patient Risk Categories 
The literature indicates several patient characteristics are clinically important to 
the long term survival of HCT recipients. To determine patient risk, we chose four 
characteristics that have been consistently reported across studies to be associated with 
survival following HCT: age at transplant, HLA match status, Karnofsky performance 
score and comorbidities.5-18 
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We used binary risk indicators for the four patient characteristics to create a risk 
score for overall mortality that ranged from 0-4. Transplant recipients over the age of 40 
(score of 1) were considered to be higher risk than their younger counterparts (score of 
0). 6 The Karnofsky performance status is used to determine the functional status of a 
recipient and can range from 0-100. A Karnofsky performance score of 90-100 
categorizes patients with the ability to carry on normal activity and no special care is 
needed (see appendix 1 for a full list of Karnofsky performance scoring). CIBTMR 
categorizes the Karnofsky performance score as a dichotomous variable of 90-100 
(score of 0) and ≤ 80 (score of 1). Coexisting disease is a binary category of diseases 
collected by CIBMTR. CIBMTR codes HCT patients with any of 18 comorbidities as 
coexisting disease present (score of 1). The HLA match status of donors describes the 
degree of immunologic similarity between recipients and donors.  HLA 8/8 match or well 
matched unrelated, and HLA matched sibling or synergenic HCTs were scored as 0 and 
any mismatched unrelated (HLA 6/8, or 7/8 matched, partially matched, or mismatched) 
or mismatched related HCTs were scored as 1. Prior to consolidating the related and 
unrelated HLA matched HCT groups within our risk category we created separate risk 
categories for each transplant group and independently verified our models for each 
group (Appendix 3).    
We considered patients with all four risk components {(a) HLA mismatch, (b) 
coexisting disease, (c) age >40, and (d) Karnofsky performance score<80)} to be the 
highest pre-transplant risk within our analytical cohort (scored with a risk category of 4). 
Conversely, transplant recipients with a risk category score of 0 {(a) HLA match, (b) no 
coexisting disease, (c) age ≤40, and (d) Karnofsky performance score ≥90)} were 
considered to have the lowest risk within our cohort. Patients with a risk category score 
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of 1, 2 and 3 were considered to have moderate pre-HCT risk.  Figure 1 is a summary of 
characteristics included in the risk categories. 
 
{Figure 2 Here} 
 
Overall survival for patients with scores of 1 and 2 were similar and hence, we 
combined them into a single group. We had a total of four risk groupings. A risk score of 
(a) 0, (b) combined 1 and 2, (c) 3 and (d) 4. Based on our pre HCT patient risk score 
categories, we categorized centers into either high or low risk centers. Centers that 
performed HCTs with only lower risk patients (risk score=0-3) were considered to be low 
risk centers. Of the 147 centers, 73 centers (N=1,984 transplants) performed only lower 
risk HCT (risk score=0-3).  To confirm that our risk categories were illustrative of distinct 
patient risk we used Kaplan-Meier methods to illustrate the difference in survival 
probability for our risk categories and observed distinct differences between all four 
groups. 
{Figure 3 Here} 
 
Center Characteristics  
High risk centers were categorized as any center that performed HCT for patients 
with the highest risk category score of 4 (N=74 high risk centers). Low risk centers were 
categorized as centers that did not perform HCT for the highest risk category score 
(N=73 low risk centers). Using organizational lists we linked the CIBTMR data to 
publically available center characteristics.  Center accreditation characteristics included 
Foundation for the Accreditation of Cellular Therapy (FACT) organizational, Academic 
Health Centers, National Cancer Institute Comprehensive Cancer centers and core 
clinical trial network certified (CTN) center status. We also created a binary indicator 
(yes/no) of centers that performed Cord Blood transplants which are considered to be 
higher risk transplants. In addition to the accreditation status of centers we recorded 
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several other center characteristics including 10 Department of Health and Human 
Services (HHS) regions and we created a high volume center (>mean transplants) 
indicator.  To adjust for possible high risk center effects and the inclusion of unrelated 
donors in our cohort, a transplant center and related/unrelated donor indicator was 
added to all multivariate models as frailty variables.  
Statistical Analysis 
We evaluated differences in risk categories and patient characteristics across all 
years. We further tested for trends in the proportion of patients in each risk category. To 
assess whether pre-transplant risk trends changed over time, we used the Cochrane-
Armitage trend test. Additionally, we evaluated differences in risk categories and patient 
characteristics using the chi-square test.  
After assessing the unadjusted relationship we evaluated the association 
between our risk categories and 3 year hazard of death using Kaplan-Meier methods 
and Cox proportional hazards modeling. Separate Kaplan-Meier curves were used to 
estimate the 3 year cumulative mortality across the risk categories for patients within 
centers that performed high risk transplants (n=74 centers) and for transplant centers 
that did not perform high risk transplants (n=73 centers) within our analytical period.  
Three separate multivariable Cox models were used to compare the impact of pre-
transplant risk factors independently for high and low risk centers and an overall 
combined models. The combined Cox model, in which patients from high and low risk 
centers were included together, adjusted for patient factors as well as a bivariate high 
risk center indicator (yes/no) and the inclusion of higher risk unrelated donors.  
In all models, we performed several sensitivity analyses such as the removal of 
non-statistically significant factors and to ensure that the observed effects were not a 
product of our risk categories and modeling decisions.  We compared models with our 
risk score and those that included each risk component measured separately to verify 
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that there was statistical benefit to the creation and inclusion of our risk scores (appendix 
2, 4, 7).  Prior to consolidating related and unrelated transplant groups within our risk 
category, we created separate risk categories for each transplant group and 
independently verified our models for each group (appendix 3).  In addition to using 
coexisting disease as a binary variable (yes/no), coexisting disease HCT index scores 
have been developed in order to more accurately capture comorbidity. Sorror et al. 
modified the established and more broadly applicable HCT index score by incorporating 
additional parameters with greater relevance in HCT and by assigning scores (1, 2, or 3) 
with better discriminating power to individual parameters. 11-13 While we acknowledge 
that the HCT comorbidity index (CI) and the Sorror comorbidity score are more accurate 
representations of patient comorbidities, the variable was underreported by centers 
relative to patient co-existing disease. Nevertheless, we conducted sensitivity analyses 
utilizing the sorror comorbidity score that did not produce results of different magnitude 
or direction (appendix 8). We conducted separate survival analyses with the use of 
hierarchical linear models to verify that accounting for transplant recipients being nested 
in centers did not produce results of different magnitude or direction (appendix 5). We 
performed separate Cox analyses to verify that our proportional hazard ratios were not a 
product of our high risk cohort (appendix 6) and volume. Under all assumptions, 
conclusions remain unchanged. See appendix for complete descriptions of sensitivity 
analysis results. SAS version 9.3 (SAS Institute) was used for all analyses. P values 
were 2 sided with a level of significance of ≤.05.  
Results 
Our cohort included 12,436 allogeneic transplants conducted in 147 centers. This 
consisted of 5,708 (46%) related transplants and 6,728 unrelated transplant recipients 
(54%). Of the related transplants 5,082 were from a HLA identical related (89%) and 92 
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(2%) were syngeneic transplants, whereas 532 (9%) of the related transplants were 
performed using a mismatched relative. Within our unrelated transplant cohort, 5,131 
(76%) underwent transplantation from HLA-matched, unrelated donors, and 1,597 (24%) 
received HLA-mismatched transplantation (≤7/8, partially matched or mismatched 
unrelated donor). Our total cohort consisted of 6,026 recipients (48%) with acute 
myelogenous leukemia (AML) and myelodysplastic syndromes (MDS), 2,174 (17%) 
patients with hodgkin lymphoma (HL) or non-hodgkin lymphoma (NHL) and 1,736 (14%) 
patients with other leukemia or myeloproliferative syndromes (MPS). The frequency of 
other diseases is shown in Table 3.  
Over the half of our patient cohort was over the age of 40, and 36 percent of our 
cohort were determined to carry on normal activity with special care needed prior to 
transplantation (Karnofsky performance scoring <80). Nearly 66% of our population was 
classified by CIBMTR to have coexisting disease prior to transplant. The annual volume 
of total HCT increased from 3,712 in 2008 to 4,458 in 2010.  
{Table 3 Here} 
Over the 2008-2010 period, the annual volume of patients in all risk categories 
increased from 2008 to 2010 with the exception of our lowest risk patients (risk 
category=0).  To investigate the differences between centers that perform higher risk 
transplants versus centers that accommodate a lower risk transplant population we 
evaluated the trends in risk category distribution. Of particular interest, within centers 
that performed higher risk transplants the proportion of the lowest risk transplant 
recipients (age 18-40, Karnofsky performance score lower than 90, no comorbidity, and 
HLA matched related or unrelated donor) decreased significantly by 28% from 6.8 
percent in 2008 to 4.9 percent in 2010 (p= 0.0005). 
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Characteristics by Type of Center: Disease groups, Regional and Volume Differences for 
High and Low Risk Centers   
The disease group distribution of patients by their risk category components in 
high and low risk centers was similar. The distribution of AML and MDS from 2008-2010 
represented the largest cohort of patients receiving HCT in both types of centers. In high 
risk centers, 5,101 (49%) of the patient population had AML and MDS while the patient 
population of low risk centers were composed of 47% (N=925) of patients with AML and 
MDS.  NHL and HL was the second most common diagnosis amongst both low and high 
risk centers with 18 percent of the high risk center patients diagnosed with NHL and HL 
and 17 percent of low risk centers. The frequency of other diseases stratified by high 
and low risk center is shown in Table 2A-2C.  
{Table 4A-4C Here} 
HCTs were performed in all 10 HHS regions. Overall, we found the highest 
concentration of HCT centers in Region 4 (AL, FL, GA, KY, MS, NC, SC, TN) and 
Region 5 (IL, IN, MI, MN, OH, WI) with 27 and 25 centers respectively. Nearly 70% of 
centers within each region performed moderate risk HCT (RC=1/2/3). Of centers that 
performed moderate risk HCT, most were Academic Health Centers, Core Clinical Trial 
Network centers, and National Cancer Institute Comprehensive Cancer Centers 
(NCICCC). Of the 74 centers performing high risk transplants nearly all performed 
transplants in all risk category categories, with the exception of five centers that did not 
perform any lowest risk level transplants.  
We further observed the frequency of center accreditation characteristics 
amongst our low risk and high risk centers, including the frequency of, Foundation for 
the Accreditation of Cellular Therapy (FACT) Centers, NCICCC, Academic Health 
Centers, Core Clinical Trial Network Center and Cord Blood Transplant Centers. We 
found that low risk centers were less likely to be FACT accredited (63% of low risk 
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centers were non-FACT centers), NCICCC (11 centers) and participate as a core clinical 
trial network center (6 centers). Conversely 81% of high risk centers were core clinical 
trial network centers and 72% were designated as NCICCC.     
{Figure 4 Here} 
In addition to being well accredited, high risk centers were generally higher 
volume centers. The mean HCT volume per center performed from 2008-2010 was 85 
transplants (Range 2 transplants-529 transplants). The mean transplant volume per 
center in high risk centers was 141 transplants, while low volume centers had a mean 
transplant volume per center of 27 transplants from 2008-2010. Higher volume in high 
risk centers was not driven by high risk patients. Instead, high risk centers primarily 
focused on the lowest and moderate risk population (risk categories=0/1/2). 
Association between Risk Category and Mortality 
Unadjusted Kaplan Meier mortality estimates showed significantly higher 3 year 
overall mortality among patients in risk category=4 (Figure 3). When we stratified high 
and low risk transplant centers we found our Kaplan Meier mortality estimates 
unchanged. Specifically, our estimates showed that patients with RC=0 had the lowest 3 
year overall mortality (median survival:  942 days), while the high risk (RC=4) group had 
significantly higher mortality (median survival: 243 days). We also found similar 3 year 
survival results for low risk patients in high risk centers (62% survival probability) and low 
risk patients in low risk centers (61% survival probability).   
{Figure 5A-5B Here} 
After adjusting for race, sex, year of transplant, HHS region and broad disease 
categories we found that, our pre-transplant risk groups were all significantly associated 
with higher relative hazard of death (adjusted hazard ratio (HR): 1.72; 95% Confidence 
Interval (1.51-1.96) for RC=1 & 2 vs. 0, adjusted HR: 2.55; 95% Confidence Interval 
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(2.227-2.92) for RC=3 vs. 0 and adjusted HR: 3.37; 95% Confidence Interval (2.835-
4.016) for RC=4 vs. 0 ).  
{Table 5 Here} 
In all centers, race, hematological condition, region (region 2, region 3, region 4, 
region 6, and region 7) and volume were all associated with 3 year relative hazard of 
death (p<0.05 for all).  
 When we stratified centers by risk type we observed similar patterns. In high risk 
centers, after adjusting for race, sex, year of transplant, HHS region and broad disease 
categories we found that, our pre-transplant risk groups were all significantly associated 
with relative hazard of death relative to risk score=0 (adjusted hazard ratio (HR): 1.6; 
95% Confidence Interval (1.404-1.902) RC=1 & 2 vs. 0, adjusted HR: 2.464; 95% 
Confidence Interval (2.107-2.881) RC=3 vs. 0 and adjusted HR: 3.2; 95% Confidence 
Interval (2.674-3.904) RC=4 vs. 0 ).  
Low risk patients in low risk centers had similar relative hazard of death 
estimates compared to low risk patients in high risk centers. Specifically, in our cohort of 
lower risk centers, after adjusting for race, sex, year of transplant, HHS region and broad 
disease categories we found that, our pre-transplant risk groups were all significantly 
associated with higher relative hazard of death (adjusted hazard ratio (HR): 1.97; 95% 
Confidence Interval (1.523-2.552) RC=1 & 2 vs. 0, adjusted HR: 2.77; 95% Confidence 
Interval (2.069-3.702) RC=3 vs. 0).  
Discussion 
The last several decades has witnessed a remarkable expansion of HCT use 
both in the U.S. and globally. We find it noteworthy that while half our cohort of centers 
continues to explore new clinical successes with higher risk patients they do not 
demonstrate superior results for low and moderate risk patients. Relative to centers that 
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avoid the highest risk patients, we observed lower risk patients in high risk centers to 
have comparable outcomes.  
Our risk groups are consistent with the pre-transplant risk literature that finds 
age, coexisting disease, Karnofsky score and HLA match levels to be significant 
indicators of overall HCT survival. Our risk category score allowed us to stratify low and 
high risk centers and to explore differences in survival for lower risk HCT patients. We 
sought to illustrate potential center level benefits of performing high risk HCT for overall 
center performance. We did not find any obvious differences or advantages for lower risk 
patients in high risk centers.   
Our study builds upon previous studies examining the implications of pre-
transplant risk on overall survival. Much of the literature has focused on validating 
various pre-HCT risk groupings. We use the literature as a starting point for our analysis 
and based on the established assumption that HCT survival varies by pre-transplant risk 
groupings.  
Our analysis begins to move beyond the validation process of risk groups and 
focuses on the value of stratifying risk by centers both willing and unwilling to perform 
high risk transplants. Higher volume centers were more likely to perform higher risk 
transplants. However, higher risk volume did not drive overall patient volume in higher 
risk centers. Instead, our results indicate that higher risk centers focused most of their 
HCT procedures on the lower risk population. To a certain extent, this leads us to 
believe that the resources to treat lower risk patients in high risk centers are depleted. 
Research has previously shown that providers with more experience (‘learning by doing’) 
produce better outcomes. Although the surgical literature has shown a direct relationship 
between procedure volume and survival 19-25, our results point to the fact that higher 
procedure volume, and a willingness to take on riskier transplants does not directly 
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translate into improved outcomes for all other patients. Our results indicate that the fact 
that larger higher volume centers appeared to be more likely to take on pre-transplant 
risk cannot simply be a product of clinical expertise (more procedures increases 
experience). If indeed volume was a surrogate for HCT expertise we would expect 
higher risk centers to have superior outcomes for all risk categories.  
This finding has important policy implications. What distinguishes risk taking 
centers from other centers is simply that a portion of their procedure population has 
higher pre-transplant risk and not that they perform all other transplants with equal 
dexterity. HCT center administrators and managers need not expect that the 
performance of higher risk HCT provides benefits in survival for lower risk patients.   
Although our results cannot provide insight into the factors that patients may 
consider prior to considering a transplant center, including other clinical factors, cost and 
insurance coverage, our results point to the fact that higher volume centers attract 
various pre-transplant risk recipients to their centers and that there are other 
unmeasured factors that are common in both large versus small centers that provide 
similar outcomes. For lower risk patients, this is an important distinction that can help 
guide their decision to transplant at a lower volume and lower risk centers and expect 
similar rates of survival. More research is needed to determine if designated centers of 
excellence offer substantial benefits over other centers for lower risk or less complex 
patients. Patient and payer policy implications could include initiatives that reduce travel 
for low risk patients. 
Although our study provides further insight into the relationship between risk 
stratification and HCT center specific survival we acknowledge data related limitations. 
The data we received from CIBMTR did not include post-transplant complications. We 
are unable to comment on post-transplant care and complications differences between 
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high and low risk centers. Additionally, our analysis only included three years of data. 
This limited our ability to measure a risk category trend over time or observe centers that 
crossed over from being low risk centers to high risk centers.   
There are additional factors that may explain survival that we did not include in 
our model. For example, we did not include the CMV serostatus of donor and recipient, 
GVHD prophylaxis regimen, disease risk, cytogenetic and molecular prognostic factors, 
and whether treatment was performed on or off a clinical trial as the CIBMTR collects 
limited information on some of these variables at the registration level. Due to the fact 
that CIBMTR broadly identifies coexisting disease as either present or absent and 
because patient inclusion within a risk category may be a construct of a center’s 
willingness to both over and under code the presence of a coexisting disease, we tested 
our risk categories with and without the inclusion of co-existing disease in our models. 
Despite these data limitations, we believe that our risk category groups provide practical 
benefit for clinicians and patients alike to stratify centers into risk categories.  
The SCTRA was passed in order to establish a more transparent transplant 
outcomes research environment in which center results could easily be retrieved by 
clinicians and HCT recipients. Novel clinical approaches have expanded HCT to a more 
complex case mix of patients and increased risk for HCT will certainly continue to be 
more common in the coming decades. Still, our results show HCT remains associated 
with significant mortality for all pre-transplant risk categories and that there is indeed no 
difference between centers when stratified for risk. However, the broader relationship 
between a center’s specific HCT survival rates remains complex, requiring a deeper 
understanding of the causal mechanisms involved in individual transplant centers and 
finding specific factors that could be introduced to all centers to improve outcomes. 
Particularly given the SCTRA, the increased transparency of information and stronger 
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ties of quality and transplant related readmission to payment provides transplant 
recipients with a more balanced choice of transplant center. While our work begins this 
stratification process, our results suggest the need for additional research using 
longitudinal data and corresponding methods to investigate the factors that more broadly 
predict the characteristics of superior centers and improve survival for all levels of pre-
transplant risk.   
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Figure 2: Summary of Characteristics Included in the Risk Categories 
 
Summary of Characteristics Included in the Risk Categories 
High Risk (Risk Category Score=4) 
Moderate Risk  
(Risk Category Score=1,2,3) 
Patients with 1,2 or 3 of the 
following:  
Low Risk (Risk Category 
Score=0) 
 Age > 40   Age > 40   Age ≤40 
 Coexisting disease  Coexisting disease 
 No Coexisting 
disease 
 HLA Mismatch (7/8, 6/8, One 
locus mismatched relative, > 
One locus mismatched relative) 
 HLA Mismatch (7/8, 6/8, One 
locus mismatched relative, > 
One locus mismatched relative) 
 HLA Match (8/8, 
Matched sibling, 
Syngeneic, Matched 
relative) 
 Karnofsky Performance Status 
score at transplant  (10 to 80) 
 Karnofsky Performance Status 
score at transplant  (10 to 80) 
 Karnofsky 
Performance Status 
score at transplant 
(90 to 100) 
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Figure 3: Unadjusted Kaplan Meier Overall 3 Year Mortality Estimates by Risk categories for all Transplant Centers 
2008-2010 
Risk Category Score=0 
Risk Category Score=4 
Risk Category Score=3 
Risk Category Score=1/2 
 44 
 
Figure 4: Center Charachtersitics of Low and High Risk Centers 2008-2010* 
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Figure 5A: Adult Unrelated and Related Overall Survival in Low Risk Centers by Risk Categories 2008-2010 
 
  240 Days 365 Days 1080 Days 
     
Risk Category=0  
Number at Risk 212 176 165 147 
Survival Probability  83% 78% 61% 
Risk Category=1/2  
Number at Risk 
146
2 1003 892 722 
Survival Probability  69% 61% 39% 
Risk Category=3  
Number at Risk 310 174 147 114 
Survival Probability  56% 48% 23% 
 
 
Risk Category Score=0 
Risk Category Score=1/2 
Risk Category Score=3 
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Figure 5B: Adult Unrelated and Related Overall Survival in High Risk Centers by Risk Categories 
2008-2010 
 
  240 Days 365 Days 1080 Days 
Risk Category=0  
Number at Risk 
586 510 482 411 
Survival Probability  87% 82% 62% 
Risk Category=1/2 
 Number at Risk 6698 5041 4533 3802 
Survival Probability  75% 68% 48% 
Risk Category=3  
Number at Risk 2749 1689 1462 1180 
Survival Probability  61% 53% 31% 
Risk Category=4  
Number at Risk 419 210 172 131 
Survival Probability  50% 41% 20% 
 
 
 
 
 
Risk Category Score=0 
Risk Category Score=1/2 
Risk Category Score=3 
Risk Category Score=4 
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Table 3: Basic Characteristics of Related and Unrelated Transplant Recipients by Risk Category (2008-2010) 
 
All 
Risk 
Bundle=0 
Risk Bundle= 
1&2 
Risk 
Bundle=3 
Risk 
Bundle=4 P-Value 
N % N % N % N % N % 
  
 Number of 
Transplant 
Recipients Total 
1243
6   798 6 8160 66 3059 25 419 3 
Transplant Year  
2008 3764 30 284 36 2483 30 885 29 112 27 0.0087 
2009 4149 33 246 31 2716 33 1031 34 156 37 
  2010 4523 36 268 34 2961 36 1143 37 151 36 
Gender            
Male  5218 42 320 40 3388 42 1334 44 176 42 0.1578 
Female 7218 58 478 6 4772 66 1725 25 243 3 
  
Patient Race  
Non-Hispanic 
White 
1023
0 82 563 71 6709 82 2605 85 353 84 <.0001 
Hispanic  976 8 126 16 657 8 176 6 17 4 
  
Black/African 
American 666 5 36 5 410 5 183 6 37 9 
Other/Multiple 
Race/Unknown 564 5 73 9 384 5 95 3 12 3 
Disease Group            
Acute 
Myelogenous 
Leukemia & 
Myelodysplastic 
Disorders  6026 48 298 37 3825 47 1657 54 246 59 <.0001 
Acute 
Lymphoblastic 
Leukemia 1523 12 201 25 1023 13 270 9 29 7 
  
Other Leukemia & 
Myeloproliferative 
Syndromes 1736 14 77 10 1158 14 434 14 67 16 
Non-Hodgkin 
lymphoma (NHL) 
& Hodgkin 
Lymphoma (HL)  2174 17 140 18 1508 18 473 15 53 13 
Other Malignancy 565 5 8 1 385 5 156 5 16 4 
Severe Aplastic 
Anemia 320 3 58 7 193 2 61 2 8 2 
Other Non-
Malignant Disease 92 1 16 2 68 1 8 0 0 0 
Centers by 
Department of 
Health and 
Human Services 
Regions  
Region 1:  
(CT, ME, MA, NH, 
RI, & VT) 1025 8 73 9 712 9 205 7 35 8 <.0001 
Region 2: (NJ, NY)  
1132 9 74 9 709 9 291 10 58 14 
  
Region 3:  
(DE, DC, MD, PA, 
VA, WV) 1329 11 104 13 873 11 316 10 36 9 
Region 4:  
(AL, FL, GA, KY, 
MS, NC, SC, TN) 
1937 16 74 9 1214 15 576 19 73 17 
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Region 5:  
(IL, IN, MI, MN, 
OH, WI) 2262 18 127 16 1471 18 575 19 89 21 
Region 6:  
(AR, LA, NM, OK, 
TX) 1322 11 80 10 814 10 384 13 44 11 
Region 7: 
(IA, KS, MO, NE)  618 5 18 2 384 5 190 6 26 6 
Region 8: 
(CO, MT, ND, SD, 
UT, WY)  385 3 22 3 254 3 99 3 10 2 
Region 9:(AZ, CA, 
HI, NV)  1687 14 203 25 1205 15 251 8 28 7 
Region 10  
(AK, ID, OR, WA) 
739 6 23 3 524 6 172 6 20 5 
Patient Age at 
Transplant  
18 to 29 1562 13 352 56 974 13 66 2 0 0 <.0001 
30 to 39 1392 11 0 44 1693 12 684 2 0 0 
  
40 to 49 2487 20 0 0 2557 21 1193 22 143 26 
50 to 59 3893 31 0 0 1725 31 970 39 152 34 
60 to 69 2847 23 0 0 148 21 93 32 14 36 
>70  255 2 0 0 148 2 93 3 14 3 
Patient Karnofsky 
Performance 
Status score at 
transplant  
90-100 7997 64 798 100 6556 80 643 21 0 0 <.0001 
≤80 4439 36 0 0 1604 20 2416 79 419 
10
0   
Coexisting 
Disease  
Absent 4516 36 798 100 3576 44 142 5 0 0 <.0001 
Present 7920 64 0 0 4584 56 2917 95 419 
10
0   
HLA Matching 
Unrelated Donor  
Matched 
Unrelated   5131 76 0 100 3589 86 1067 62 23 0 <.0001 
Mismatched 
Unrelated 1597 24 29 0 303 14 245 38 73 
10
0   
HLA Matching 
Related Donor  
Mismatched 
Relative 532 9 0 0 189 5 247 19 96 
10
0 <.0001 
Matched Relative 5176 91 408 100 3703 95 1065 81 0 0   
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Table 4A: Disease Groups of Related and Unrelated Transplant Recipients by Risk Category for All Centers (2008-2010) 
 
All Risk Category=0 Risk Category=1&2 Risk Category=3 Risk Category=4 
Disease Group N % N % N % N % N % 
Acute Myelogenous 
Leukemia & 
Myelodysplastic 
Disorders 6026 48 298 37 3825 47 1657 54 246 59 
Acute 
Lymphoblastic 
Leukemia 1523 12 201 25 1023 13 270 9 29 7 
Other Leukemia & 
Myeloproliferative 
Syndromes 1736 14 77 10 1158 14 434 14 67 16 
Non-Hodgkin 
lymphoma (NHL) & 
Hodgkin Lymphoma 
(HL) 2174 17 140 18 1508 18 473 15 53 13 
Other Malignancy 565 5 8 1 385 5 156 5 16 4 
Severe Aplastic 
Anemia 320 3 58 7 193 2 61 2 8 2 
Other Non-
Malignant Disease 92 <1 16 2 68 <1 8 <1 0 0 
 
Table 4B: Disease Groups of Related and Unrelated Transplant Recipients by Risk Category for High Risk Centers (2008-2010) 
 
All 
Risk 
Category=0 Risk Category=1&2 Risk Category=3 Risk Category=4 
Disease Group N % N % N % N % N % 
Acute Myelogenous 
Leukemia & 
Myelodysplastic 
Disorders 5101 49 234 40 3145 47 1476 54 246 59 
Acute Lymphoblastic 
Leukemia 1229 12 140 24 825 12 235 9 29 7 
Other Leukemia & 
Myeloproliferative 
Syndromes 1496 14 59 10 978 15 392 14 67 16 
Non-Hodgkin lymphoma 
(NHL) & Hodgkin 
Lymphoma (HL) 1830 18 100 17 1242 19 435 16 53 13 
Other Malignancy 493 5 7 1 320 5 150 5 16 4 
Severe Aplastic Anemia 248 2 39 7 147 2.19 54 2 8 2 
Other Non-Malignant 
Disease 55 <1 7 1 41 <1 7 <1 0 0 
 
Table 4C: Disease Groups of Related and Unrelated Transplant Recipients by Risk Category for Low Risk Centers (2008-2010) 
 
All Risk Category=0 Risk Category=1&2 Risk Category=3 
Disease Group N % N % N % N % 
Acute Myelogenous Leukemia 
& Myelodysplastic Disorders 925 47 64 30 680 47 181 58 
Acute Lymphoblastic 
Leukemia 294 15 61 29 198 14 35 11 
Other Leukemia & 
Myeloproliferative 
Syndromes 240 12 18 8 180 12 42 14 
Non-Hodgkin lymphoma 
(NHL) & Hodgkin Lymphoma 
(HL) 344 17 40 19 266 18 38 12 
Other Malignancy 72 4 1 0 65 4 6 2 
Severe Aplastic Anemia 72 4 19 9 46 3 7 2 
Other Non-Malignant Disease 37 2 9 4 27 2 1 <1 
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Table 5: Factors Associated with 3 Year Relative Hazard of Death among HCT Patients, Cox Proportional Hazard Models, Hazard Ratio, 95% CI 
 
Cox Model ALL Cox Model High Risk Centers Cox Model Low Risk Centers 
 
Hazard 
Ratio 
95% CI P Value 
Hazard 
Ratio 
95% CI P Value Hazard Ratio 95% CI P Value 
Risk Categories  
0 REF REF REF 
1/2 1.721 1.51 1.961 <.0001 1.634 1.404 1.902 <.0001 1.971 1.523 2.552 <.0001 
3 2.552 2.227 2.925 <.0001 2.464 2.107 2.881 <.0001 2.768 2.069 3.702 <.0001 
4 
3.374 2.835 4.016 <.0001 3.231 2.674 3.904 <.0001 - - - - 
Gender  
Male REF REF REF 
Female 0.914 0.868 0.963 0.0007 0.923 0.872 0.977 0.0058 0.871 0.766 0.99 0.035 
Patient Race  
Non-Hispanic White REF REF REF 
Hispanic 1.055 0.954 1.166 0.2955 1.072 0.956 1.201 0.2327 1.004 0.811 1.244 0.9697 
Black/African 
American 1.16 1.038 1.296 0.0087 1.056 0.927 1.203 0.4094 1.552 1.247 1.932 <.0001 
Other/Multiple 
Race/Unknown 0.993 0.871 1.133 0.9215 0.964 0.835 1.112 0.611 1.216 0.874 1.692 0.2456 
Transplant Year  
2008 REF REF REF 
2009 1 0.939 1.064 0.9877 0.977 0.913 1.046 0.5083 1.115 0.956 1.302 0.1663 
2010 1.007 0.942 1.076 0.8375 0.99 0.92 1.066 0.7955 1.093 0.929 1.287 0.2834 
Disease Group  
Acute Myelogenous 
Leukemia & 
Myelodysplastic 
Disorders 
REF REF REF 
Acute Lymphoblastic 
Leukemia 0.992 0.915 1.077 0.8562 0.96 0.876 1.052 0.3805 1.129 0.94 1.357 0.1949 
Other Leukemia & 
Myeloproliferative 
Syndromes 0.763 0.704 0.827 <.0001 0.749 0.686 0.818 <.0001 0.849 0.693 1.04 0.1143 
Non-Hodgkin 
lymphoma (NHL) & 
Hodgkin Lymphoma 
(HL) 0.829 0.771 0.892 <.0001 0.823 0.76 0.892 <.0001 0.865 0.722 1.037 0.1165 
Other Malignancy 0.929 0.822 1.05 0.2371 0.926 0.811 1.056 0.252 0.926 0.666 1.288 0.6496 
Severe Aplastic 
Anemia 0.548 0.445 0.675 <.0001 0.644 0.514 0.806 0.0001 0.296 0.17 0.516 <.0001 
Other Non-Malignant 
Disease 0.627 0.436 0.901 0.0116 0.712 0.441 1.15 0.1647 0.526 0.3 0.923 0.0251 
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 Cox Model ALL Cox Model High Risk Centers Cox Model Low Risk Centers 
 
Hazard 
Ratio 
95% CI P Value 
Hazard 
Ratio 
95% CI P Value 
Hazard 
Ratio 
95% CI P Value 
Centers by 
Department of Health 
and Human Services 
Regions 
 
Region 1: (CT, ME, 
MA, NH, RI, & VT) 
REF REF REF 
Region 2: (NJ, NY) 1.146 1.013 1.298 0.0308 1.126 0.988 1.283 0.0751 1.422 0.935 2.164 0.0999 
Region 3: (DE, DC, 
MD, PA, VA, WV) 1.203 1.066 1.357 0.0027 1.209 1.06 1.379 0.0047 1.235 0.848 1.797 0.2709 
Region 4: (AL, FL, GA, 
KY, MS, NC, SC, TN) 1.124 1.005 1.257 0.0403 1.134 1.007 1.277 0.0379 1.136 0.787 1.639 0.4969 
Region 5: (IL, IN, MI, 
MN, OH, WI) 1.082 0.968 1.209 0.1655 1.072 0.953 1.207 0.2465 1.183 0.812 1.723 0.3818 
Region 6: (AR, LA, NM, 
OK, TX) 1.194 1.059 1.346 0.0037 1.24 1.092 1.409 0.0009 1.074 0.729 1.582 0.7174 
Region 7:(IA, KS, MO, 
NE) 1.287 1.117 1.482 0.0005 1.295 1.118 1.5 0.0006 1.408 0.807 2.456 0.2286 
Region 8:(CO, MT, ND, 
SD, UT, WY) 1.083 0.911 1.288 0.3634 1.081 0.907 1.287 0.3849 0 0 4E+154 0.9531 
Region 9:(AZ, CA, HI, 
NV) 1.062 0.943 1.196 0.3225 1.016 0.896 1.153 0.8032 1.338 0.9 1.988 0.1498 
Region 10 (AK, ID, OR, 
WA) 
1.057 0.918 1.218 0.439 1.052 0.911 1.214 0.4935 0.952 0.128 7.065 0.9617 
Center Characteristics  
Low Volume Indicator 
(≤55 Transplants) 
REF REF REF 
High Volume Indicator 
(>55 Transplants) 1.205 1.099 1.322 <.0001 1.333 1.171 1.518 <.0001 1.184 1.024 1.368 0.0226 
Related Donor 
Indictor 
REF REF REF 
Unrelated Donor 
Indicator 1.151 1.092 1.214 <.0001 1.142 1.078 1.211 <.0001 1.202 1.056 1.369 0.0054 
FACT Status (no) REF REF REF 
FACT Status (yes) 0.958 0.843 1.088 0.5050 1.128 0.943 1.351 0.1883 0.865 0.702 1.065 0.1714 
Low Risk Center 
Indicator 
REF  
 
High Risk Center 
Indicator 1.136 1.048 1.232 0.002 - - - - - - - - 
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Chapter 4: The Impact of Center Accreditation on Hematopoietic Cell Transplantation (HCT): 
Should HLA Mismatched HCT be Restricted to Foundation for the Accreditation of Cellular 
Therapy (FACT) Centers and Core Clinical Trial Network Centers? 
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Background: Hematopoietic cell transplantation (HCT) is the transplantation of stem 
cells from a related or unrelated donor for the treatment of many hematologic 
malignancies. The choice of donor is based on compatible human leukocyte antigen 
(HLA). HLA match quality (8/8 loci) is an essential component of higher survival rates 
among HCT recipients and whenever possible, HLA mismatching (7/8 loci) is avoided. 
There are two voluntary center accrediting organizations, The Foundation for the 
Accreditation of Cellular Therapy (FACT) and core clinical trial network certification 
(CTN) that are thought to improve and ensure HCT center quality care, engage in 
rigorous donor and cell selection criteria and certify clinical excellence.  We sought to 
observe whether there are differences in outcomes among HLA matched and 
mismatched HCT by CTN and FACT status.  
Methods: Using the 2008-2010 Center for International Blood & Marrow Transplant 
Research (CIBMTR) data we created three center categories (a) non-FACT centers 
(n=24 centers)  (b) FACT-only certified centers (N=106 centers) and (c) FACT and core 
clinical trial network (FACT/CTN) certified centers (N=32 centers). We identified HLA 
match categories and patient characteristics within our centers and the relationship 
between FACT certification and survival. The association between our center categories 
and hazard of death was evaluated using Cox proportional hazard modeling. 
Results: Our transplant cohort consisted of 12,993 transplants conducted in 162 
centers. The number of total HCTs increased from 3,984 in 2008 to 4,639 in 2010. Over 
time, the number of patients in all categories (related and unrelated, HLA matched and 
mismatched) increased.  After adjusting for patient and center characteristics we found 
that FACT/CTN centers had consistently superior results relative to non-FACT and 
FACT only centers (p<0.05). However, non-FACT centers were comparable to FACT-
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only centers for matched related and unrelated patients. FACT/CTN centers showed 
particular superiority for more complex HCT.  
Conclusions: Current attempts to improve and ensure HCT quality care and certify 
clinical excellence include voluntary center participation in FACT. Our findings imply that 
FACT/CTN centers have better survival rates than other accredited and non-accredited 
centers and are particularly superior at treating more complex HLA mismatched HCTs.  
However, we do not see fundamental differences in survival between FACT and non-
FACT centers in the less complex matched cohort. Although FACT status is an 
important standard of quality control that begins to define improved overall survival our 
results indicate that FACT status alone is not an indicator for superior outcomes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 55 
 
Background 
Allogeneic hematopoietic cell transplantation (HCT) is a complex treatment for 
several hematological disease groups and involves the infusion of donor hematopoietic 
stem cells into a recipient. In the past several decades, human leukocyte antigen (HLA) 
matching capabilities and refined methodology has buttressed clinical abilities to 
increase the successful performance of HCT. For example, donor and recipient HLA 
matches can be made on an 8 of 8 (match) or 7/8 (mismatched) HLA level for unrelated 
donor HCT. A 6/8 or lower donor recipient match is generally considered unacceptable 
for successful HCT. 40 
The search for a donor and recipient HLA match begins with the patient’s siblings 
who have the same parents as the patient. If a sibling is not a perfect match (8/8 loci are 
matched), the search moves to other immediate family members and possibly unrelated 
donors creating four total categories; HLA matched related, HLA mismatched related, 
HLA matched unrelated and HLA mismatched unrelated transplants.15-41Finding suitable 
related or unrelated donors has increasingly become more common in the last decade 
with the proliferation of HCT centers and ease of access to donor registries. It is widely 
accepted that match quality is an essential component of higher survival rates and 
improved long term outcomes among HCT recipients.15-16, 40-42 Clinical best practice 
dictates that whenever possible, HLA matched donors are preferable in regulating 
responses between donor and recipient, reducing the risk of post-transplant 
complications and infections and improving the chances for long term survival.15-16, 40-42 
The Foundation for the Accreditation of Cellular Therapy (FACT) is a non-profit 
entity co-founded by the International Society for Cellular Therapy and the American 
Society of Blood and Marrow Transplantation in 1996. 23 Its core mission is to certify the 
clinical excellence in process and outcomes of transplant centers. In addition to facility 
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certification, FACT publishes standards of excellence that are readily available to all 
centers. Specific standards include minimum of 5 HCTs annually, guidelines for HCT 
center laboratories and clinical oversight and methodologies for HLA typing and 
processing. The first edition of the FACT standards was published in 1996, and the first 
center was accredited in 1998. Accreditation is awarded after successful documentation 
of compliance with the current FACT standards and an annual fee is paid. Annual on-site 
inspections are carried out by a team of clinical inspectors. 23 
FACT centers are thought to be centers of excellence that engage in rigorous 
donor and cell selection criteria and exert adequate quality control over the entire HCT 
process. Non-FACT centers may adhere to evidence based practice and levels of non-
accredited levels of excellence in process and outcomes. However, it is assumed that 
payers and providers do not recognize non-FACT accredited centers in the U.S. as 
experienced centers with fully developed clinical treatment protocols.6, 21, 23There is a 
core assumption that FACT centers adhere to standards of excellence set by clinical 
experts in the field of transplantation medicine, surgery, nursing and pharmacy that is 
unattainable by other non-accredited centers.23  
Certifying and accrediting centers of excellence are not novel approaches to 
oversee and underscore standards of excellence and health care quality and outcomes. 
There is a broad literature exploring whether there are differences in process and 
outcomes at academic health centers, accredited centers of excellence, teaching 
hospitals and the National Cancer Institute’s Comprehensive Cancer Centers (NCICCC). 
21, 48, 63-67, 71 Results have been mixed. For example, using the national Medicare 
database, Birkmeyer et al. conducted an analysis of 51 NCICCC and six cancer 
procedures, cystectomy, colectomy, pulmonary resection, pancreatic resection, 
gastrectomy, and esophagectomy cancer. 48 Although Birkmeyer did not fully account for 
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differences in patient population, she found that NCI designated cancer centers had 
lower surgical mortality rates than those treated at comparably high-volume hospitals, 
but had similar long-term survival rates.48 Meguid et al. found that in-hospital outcomes 
are superior for patients undergoing lung cancer resections at teaching hospitals, with 
results prominent at all but the highest volume institutions.63Other literature that 
analyzed either process measures of care or that assessed risk-adjusted mortality rates 
found differences in quality between major teaching hospitals and nonteaching hospitals 
across several cancer groups.68-72These differences have been reported in combined 
analyses of multiple conditions but have not always been consistent in finding significant 
results and rarely do these analyses control for center volume. 
The HCT literature that focuses on center characteristics and FACT certification 
is limited. Several transplant center characteristics have been associated with increased 
survival. Majhail et al. found that practice variation, such as physician workforce, 
transplant capacity, clinician approach to transplantation for hematologic disorders and 
choice of graft source can impact the quality of care for transplant recipients. 19 Using 
Center for International Blood & Marrow Transplant Research data from 1998-2000, 
Loberiza et al. found significant survival differences for patients receiving allogeneic HCT 
in centers with one or more favorable center related factors such as physician caseload, 
contact for afterhours call and medical school affiliation. 20 However, Loberiza did not find 
an association between factors that might be expected to correlate with increased levels 
of survival such as FACT accreditation (yes/no) and NCICCC designation.  
In addition to FACT accreditation, centers hold a variety of other credentials 
including NCICCC, Academic Health Center status, Accreditation Council for Graduate 
Medical Education-approved centers and Center of Excellence Designation by Medical 
Insurance Plans. These are highly correlated to each other. In 2001, With the support of 
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the National Cancer Institute and the National Heart, Lung, and Blood Institute, the Blood 
and Marrow Transplant Clinical Trials Network (CTN) was established.38 Currently, there 
are 32 centers that participate as “core” centers within the U.S. with the goal of 
conducting phase II and III multicenter trials to address clinical issues in HCT and offer 
trial participation to patients in all regions of the United States. For this study we created 
three center categories that included non-FACT centers, FACT-only accredited centers 
and FACT and core CTN centers (FACT/CTN). 
The literature has previously found no significant differences between FACT and 
non-FACT centers. As FACT accreditation has become more common among centers 
(approximately 90% of U.S. HCT centers are accredited), we created a third center 
category in order to determine if FACT accreditation and clinical trial participating 
centers demonstrated a high level of excellence. Additionally, in order to account for 
patient complexity, we sought to determine if accreditation had any impact on the 
survival of HLA mismatched HCT. Specifically, our goal is to broaden the scope of the 
accreditation and HCT literature by assessing if there are differences in outcomes 
among HLA matched and mismatched HCT by FACT and CTN status.  
Methods 
Data Source 
The Center for International Blood & Marrow Transplant Research (CIBMTR) is a 
research affiliation of the International Bone Marrow Transplant Registry, Autologous 
Blood and Marrow Transplant Registry, and National Marrow Donor Program (NMDP) 
that was established in 2004. CIBMTR is comprised of a voluntary working group of 
more than 450 transplantation centers worldwide that contribute detailed data on 
consecutive HCT to a Statistical Center at the Medical College of Wisconsin in 
Milwaukee, WI and the NMDP Coordinating Center in Minneapolis, MN. In addition, the 
CIBMTR holds the contract for the Stem Cell Therapeutic Outcomes Database part of 
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the CW Bill Young Transplantation Program from the Human Resources and Services 
Administration; as a part of this Program, all transplant centers in the US are mandated 
to report clinical outcomes data for allogeneic HCT to the CIBMTR. All CIBMTR teams 
contribute registration data (also called transplant essential data (TED)). These data 
include disease type, age, sex, pre-transplant disease stage, date of diagnosis, graft 
type, conditioning regimen, post-transplant disease progression and survival, 
development of a new malignancy, and cause of death. TED level data are collected 
before transplant, 100 days and 6 months after transplant, and annually thereafter or 
until death. We obtained a de-identified dataset from CIBTMR. Our study was deemed 
exempt from review by the Human Subjects Committee of the University of Minnesota’s 
Institutional Review Board.  
FACT Center Categories and Center Characteristics  
We linked our CIBMTR data to a publically available FACT organizational list and 
the core clinical trial network certified (CTN) center status list38,83and created three 
center categories (a) non-FACT centers (n=24 centers) (b) FACT-only accredited 
centers (N=106 centers) and (c) FACT and core clinical trial network certified centers 
(FACT/CTN) (N=32 centers). FACT/CTN centers are accredited by FACT but are also 
part of HCT leadership as they conduct multicenter trials to address clinical issues in 
HCT. FACT/CTN centers are assumed by our study to adhere to a higher form of 
excellence in relation to other centers. In addition to FACT and CTN status we recorded 
several other center characteristics including 10 Department of Health and Human 
Services (HHS) regions and center volume quartiles.   
Patient Variables 
We included transplant recipients 18 years or older who received transplants 
between January 1, 2008, through December 31, 2010 and were reported to the 
CIBTMR. We included patients who received peripheral blood stem cells or bone 
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marrow graft from HLA-matched or mismatched, related or unrelated donors.  All 
diagnoses, the 4 level recipient and transplant donor match category (matched related, 
mismatched related, matched unrelated and mismatched unrelated), coexisting disease, 
and patient Karnofsky score were included.  
The Karnofsky performance status is used to determine the functional status of a 
recipient and can range from 0-100. A Karnofsky performance score of 90-100 
categorizes patients with the ability to carry on normal activity and no special care is 
needed. 84 CIBMTR categorized Karnofsky scoring as a dichotomous variable of 90-100, 
and ≤ 80. Coexisting disease is a binary category of diseases collected by CIBMTR. 
CIBMTR codes HCT patients with any of 18 comorbidities as coexisting disease present. 
85 We included patients that had missing coexisting disease information (N=406). We 
combined our matched related and unrelated patients into one category and our 
mismatched related and unrelated patients into a second category. Prior to consolidating 
related and unrelated transplant groups we created separate categories for each 
transplant group and independently verified our models for each group.   
Statistical Analysis 
We evaluated differences in FACT center status and patient characteristics 
across all years of transplantation. To assess whether the performance of mismatched 
HLA HCTs changed over time, we used the Cochrane- Armitage trend test. Additionally, 
we evaluated the differences in FACT center status and patient characteristics using the 
chi-square test.  
After assessing unadjusted relationships we used logistic regression to examine 
the association between the relative odds of mismatched related or unrelated HCT 
(yes/no), patient demographics and FACT/CTN status. Finally, we evaluated the 
association between FACT certification and 3 year hazard of death using Kaplan-Meier 
 61 
 
methods and Cox proportional hazards modeling. Kaplan-Meier methods were used to 
estimate unadjusted 3 year cumulative mortality by transplant center FACT status and 
HLA match type categories within our analytical period.  In order to capture the 
interaction between both FACT status and HLA match category we created an HLA 
match category by FACT status variable. To adjust for possible high volume center 
effects in our cohort a high volume transplant center indicator was added to all 
multivariate models as a frailty variable.  
In all models, we performed several sensitivity analyses to ensure that the 
observed effects were not a product of our FACT center classification and modeling 
decisions.  We modeled our cohort with and without the inclusion of non-FACT centers 
in order to ensure that these centers did not distort our results for the two other FACT 
categories, in which the majority of transplants were performed. We did not observe a 
change in the magnitude or direction of our results. We performed several survival 
analyses on separate sub-cohorts to ensure that various severity distinctions and 
disease groups did not alter our results. We also performed separate survival analyses 
to verify that our proportional hazard ratios were not a product of transplant volume and 
center regions and measured proportional hazard ratios for low and high volume centers 
and higher HCT concentration regions (appendix 9 and 10). Finally, we conducted 
separate analyses for related and unrelated cohorts (appendix 11a-11e). Under all 
assumptions, conclusions remain unchanged. See appendix for complete descriptions of 
sensitivity analysis results.  
SAS version 9.3 (SAS Institute) was used for all analyses. P values were 2 sided 
with a level of significance of ≤.05.  
Results 
Our final cohort consisted of 12,993 transplants conducted in 162 centers. Of 
these, 24 centers were non-FACT certified (N=559 transplants), 106 centers were 
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FACT-only certified (N=5,655 transplants), and 32 centers had FACT/CTN status 
(N=6,779 transplants). Between 2008-2010, the annual number of total transplants 
increased for all types of centers. Most of the patient cohort was classified with a 
coexisting disease (64%, N=8,279) and 62% had a Karnofsky score above 90 
(N=8,014). The majority of the patients (66%) were diagnosed with AML and MDS 
(N=6,263 transplants) or NHL and HL (N=2,320 transplants).  
{Table 6 HERE} 
We found that matched and mismatched unrelated HCT increased significantly 
over time (p<.05) while transplants in the related HCT category did not experience a 
significant increase. Matched related donors (N=5,349 transplants) or matched unrelated 
donors (N=5,419 transplants) accounted for 83% of HCTs. The percentage of unrelated 
transplants ranged from 45% within FACT/CTN centers to 48% in non-FACT centers. 
Similarly, nearly half of the transplants performed in FACT-only and non-FACT centers 
were related HCTs (47% related FACT-only HCT and 52% related non-FACT HCT). 
When the transplant population was broken down by FACT status and HLA matched or 
mismatched status, non-FACT centers performed the highest percentage of matched 
related or unrelated HCT (86%) and FACT/CTN centers performed the highest 
percentage of mismatched related and unrelated transplants (18%). FACT only and non-
FACT centers performed a similar proportion of mismatched related/unrelated 
transplants (16% and 14% respectively).  
{Figure 6A and 6B Here} 
Association between Receipt of HLA Mismatch HCT and FACT Status 
In our study, 17% of HCT patients received a mismatched related or unrelated 
transplant. We used multivariate analyses in order to examine the association between 
the relative odds of mismatched related or unrelated HCT and FACT status and the 
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likelihood of HLA mismatched HCT at non-FACT, FACT-only or FACT/CTN certified 
facilities. After adjusting for center and clinical variables, patients were significantly more 
likely to have HLA mismatched HCT at FACT/CTN certified facilities (adjusted odds ratio 
(OR) FACT/CTN versus Non-FACT, 1.43; p-value <.0001). Additional factors 
significantly associated with the increased likelihood of HLA mismatched HCT included 
race (Hispanic, African American, multiple race versus non-Hispanic white), and region 
(DHS Region 2, Region 3, and Region 9 versus Region 1).  
{Table 7 HERE} 
 
There were also factors significantly associated with a decreased likelihood of 
HLA mismatched HCT including, older age categories 40-69 (relative to ages 18-29). 
Acute Lymphoblastic Leukemia and SAA were disease categories significantly 
associated with a decreased likelihood of HLA mismatched relative to AML and MDS. 
Although transplant year was not significantly associated with mismatched HCT, the 
likelihood of mismatched transplants decreased over time.  
Association between FACT Status and Mortality 
 Unadjusted Kaplan Meier mortality estimates showed significantly higher 3 year 
overall mortality among all patients in both non-FACT and FACT-only centers relative to 
FACT/CTN. 
{Figure 7A-7C HERE} 
When we stratified matched and mismatched transplant recipients by center 
certification status we found that FACT/CTN centers had the lowest 3 year overall 
mortality among HLA matched related patients. However, non-FACT and FACT certified 
centers showed strikingly similar curves for HLA matched related recipients. Unadjusted 
Kaplan Meier mortality estimates showed significantly higher 3 year overall mortality 
among mismatched related HCTs within FACT-only centers. For the unrelated matched 
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HCT cohort both non-FACT and FACT-only centers had lower 3 year overall mortality 
than mismatched unrelated HCT recipients. These results were unchanged when we 
further restricted our cohort to high volume centers.   
Adjusted Association between FACT Status and Hazard of Death 
In order to capture the interaction between both FACT status and HLA match 
category we created an HLA match category by FACT status variable. After adjusting for 
patient and center characteristics we found that our non-FACT/mismatched HCT 
patients had the highest adjusted relative hazard of death (adjusted hazard ratio (HR): 
2.05; p-value<.0001 non-FACT/Any Mismatch vs. non-FACT/Matched). However, 
FACT/Matched patients had a higher relative hazard of death relative to Non-
FACT/Matched HCT (adjusted HR: 1.138; p-value .075 FACT/Matched vs. Non-
FACT/Matched).  
{Table 8 HERE} 
 
The FACT/CTN superiority trend persisted for mismatched HCT. However, our 
non-FACT centers performed remarkably similarly to our FACT-only centers for both 
matched and mismatched patients. Overall, our FACT/CTN centers consistently showed 
superior results for more complex mismatched HCT.   
There were also factors significantly associated with hazard of death including 
race, older age, recipient Karnofsky performance status score at transplant, and 
coexisting disease (p<0.05 for all). For disease groups, NHL and HL, Other Leukemia 
and Myeloproliferative Syndromes, Severe Aplastic Anemia and Other non-malignant 
disease (versus Acute Myelogenous Leukemia & Myelodysplastic Disorders) were all 
associated with lower 3 year relative hazard of death (p<0.05 for all). We also saw some 
regional variation. Region 3, 4, 6 and 7 showed higher relative hazard of death versus 
Region 1 (CT, ME, MA, NH, RI, & VT) (p<0.05). 
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Discussion 
In this study of 162 centers, we found that FACT/CTN accreditation was most 
strongly associated with superior overall 3 year survival. Differences in survival by FACT 
accreditation status were most apparent for more complex HCTs. Non-FACT and FACT-
only centers were less likely to perform mismatched HCT relative to FACT/CTN centers. 
After stratifying our transplant recipients by related and unrelated match categories we 
found that FACT/CTN centers were more capable of performing complex mismatched 
HCTs compared to centers with FACT-only and non-FACT accreditation status.  
Despite the inferior outcomes of mismatched HCT patients in non-FACT centers 
relative to FACT only and FACT/CTN centers, Non-FACT and FACT only centers 
performed similarly overall in the HLA matched HCT category. These results suggest 
that since FACT’s inception nearly two decades ago, FACT accreditation has become 
ubiquitous among HCT centers and that HCT techniques have consistently improved 
across all centers irrespective of accreditation status.  
Our findings are consistent with previous center accreditation literature that finds 
mixed results among accredited centers of excellence. Our findings indicate that when 
FACT centers are stratified into distinct categories, FACT/CTN accreditation status does 
imply superior overall results in the matched transplants category as compared to non-
FACT or FACT alone accredited centers irrespective of transplant volume. These 
differences are further highlighted among mismatched related and unrelated HCTs. This 
finding also implies that FACT/CTN centers are particularly superior at treating more 
complex HLA mismatched HCTs.  However, we do not see fundamental differences 
between FACT and non-FACT centers in the matched cohort. We are limited in our 
ability to comment on the apparent superiority of FACT/CTN centers because we cannot 
completely rule out explanations such as observed higher transplant volume or patient 
case mix. However, based on our sensitivity analysis we do not believe that FACT/CTN 
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centers’ superior results are due to higher transplant volume or favorable patient case 
mix. We hypothesize that one explanation for FACT/CTN superiority is the nature of the 
clinical trials conducted in FACT/CTN centers that require higher levels of national 
clinical collaboration and standardization of protocols.  
  There are several components of FACT accreditation that should in theory 
explain transplant patients’ superior results. FACT requirements are updated regularly 
with the contributions of the most innovative minds in cellular therapy and the wider 
transplant community. These organizations engage in a more transparent and open 
environment in which donor and cell selection standards are adhered to at the highest 
levels. 6, 21, 23 Although FACT accreditation sets an important center standard that begins 
to define improved overall survival, our results indicate that FACT status alone is not an 
indicator of superior outcomes.  
Our study builds upon previous studies examining the implication of FACT 
accreditation. Although Loberiza et al. did not find differences in survival between FACT 
centers vs. non-FACT centers21 we found that the differences in centers was within the 
FACT category and that not all FACT centers perform equally. Although the majority of 
our centers are FACT-only centers (106 centers), we find that non-FACT centers have 
similar relative hazard of death results to FACT-only centers.    
While our study provides important implications for center certification initiatives, 
we acknowledge several data related limitations. First, there are additional factors that 
may explain survival that we did not included in our model. For example, we did not 
include the regimen; therapy related or transformed disease, and whether treatment was 
performed on or off a clinical trial. Our FACT/CTN accredited centers were 
unquestionably more likely to perform clinical trials. The data does not indicate which of 
our centers participated in trials or which patients were enrolled in trials. Additionally, we 
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are not able to obtain detailed patient comorbidity information. Due to the fact that 
CIBMTR broadly identifies coexisting diseases as either present or absent we may 
underestimate the severity of patient complexity in certain FACT center status 
categories.  We are also limited by not knowing the clinical decision pathway in which 
providers and patients sought to find a mismatched related or mismatched unrelated 
donor. For example, some centers may choose a matched unrelated donor immediately 
after not finding a suitable matched related donor while others may search instead for a 
mismatched related donor. This decision making process would provide additional 
insight into our ability to further identify particularities in center differences for the 
mismatched related and unrelated HLA cohort. Despite these data limitations we believe 
that our results highlight differences between FACT centers and the need for additional 
research to explain the causal mechanisms involved in FACT/CTN superiority.   
In conclusion, our study has important implications for providers, policy makers 
and patients seeking a transplant center. The Stem Cell Therapeutic and Research Act 
was enacted by Congress in order to establish a more transparent transplant outcomes 
research environment in which center results could easily be retrieved by clinicians and 
HCT recipients. For nearly two decades, FACT accreditation has been promoted as 
measure of center excellence.  For example, FACT accreditation is a factor in the 
ranking of “America’s Best Hospitals,” and “America’s Best Children’s Hospitals,” 
published annually by U.S. News and World Report. Our results begin to illustrate the 
variation within FACT categories and also underscore the notion that FACT accreditation 
alone is not enough of an indicator to differentiate transplant centers. However, the 
broader relationship between FACT status and a center’s specific HCT survival rate 
remains complex, requiring a deeper understanding of the causal mechanism involved 
and finding specific factors that could be introduced to all centers to improve outcomes. 
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Learning from the evolution of accredited centers over time will provide policy makers, 
administrators and payers with information to guide future resource planning and areas 
to focus future quality improvement efforts.  
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Table 6: Basic Patient Characteristics by FACT Center Status: 2008-2010 
P-Value
N % N % N % N %
Number of Transplants 12993 559 4 5655 44 6779 52
0.0116
2008 3984 31 154 28 1803 32 2027 30
2009 4370 34 185 33 1810 32 2375 35
2010 4639 36 220 39 2042 36 2377 35
<.0001
Matched Related Donor 5419 42 287 51 2488 44 2644 39
Mismatched Related Donor  570 4 5 1 171 3 394 6
Matched Unrelated Donor 5349 41 197 35 2256 40 2896 43
Mismatched Unrelated Donor 1655 13 70 13 740 13 845 12
0.1947
Male 7543 58 345 62 3280 58 3918 58
Female 5450 42 214 38 2375 42 2861 42
<.0001
Non-Hispanic White 10669 82 444 79 4856 81 5639 83
Hispanic 1018 8 52 9 505 9 461 7
Black/African American 704 5 30 5 347 6 327 5
Other/Multiple Race/Unknown 602 5 33 6 217 4 352 5
0.0499
18 to 29 1630 13 80 14 750 13 800 12
30 to 39 1450 11 65 12 657 12 728 11
40 to 49 2586 20 108 19 1098 19 1380 20
50 to 59 4075 31 184 33 1770 31 2121 31
60 to 69 2983 23 117 21 1262 22 1604 24
≥80 269 2 5 1 118 2 146 2
<.0001
90-100 8014 62 292 52 3448 61 4274 63
≤80 4445 34 264 47 20666 37 2115 31
Missing 534 4 3 1 141 2 390 6
<.0001
Absent or Missing 4714 36 272 49 2144 38 2298 34
Present 8279 64 287 51 3511 62 4481 66
<.0001
Acute Myelogenous Leukemia & 
Myelodysplastic Disorders 6263 48 234 42 2770 49 3259 48
Acute Lymphoblastic Leukemia 1566 12 69 12 743 13 754 11
Other Leukemia & Myeloproliferative 
Syndromes 1820 14 74 13 773 14 973 14
Non-Hodgkin lymphoma (NHL) & Hodgkin 
Lymphoma (HL) 2320 18 101 18 938 17 1281 19
Other Malignancy 595 5 59 11 239 4 297 4
Severe Aplastic Anemia 332 3 13 2 154 3 165 2
Other Non-Malignant Disease 97 1 9 2 38 1 50 1
<.0001
Quartile I Volume Centers (1-5 Transplants) 102 1 22 4 80 1 0 0
Quartile II Volume Centers (6-44 Transplants) 871 7 146 26 680 12 45 1
Quartile III Volume Centers (45-107 Transplants) 2946 22 264 47 2337 41 345 5
Quartile IV Volume Centers (108-713 Transplants) 9074 70 127 23 2558 45 6389 94
<.0001
Region 1: (CT, ME, MA, NH, RI, & VT) 1066 8 25 4 313 6 728 11
Region 2: (NJ, NY) 1163 9 16 3 730 13 417 6
Region 3: (DE, DC, MD, PA, VA, WV) 1402 11 103 18 726 13 573 8
Region 4: (AL, FL, GA, KY, MS, NC, SC, TN) 1943 15 18 3 801 14 1124 17
Region 5: (IL, IN, MI, MN, OH, WI) 2341 18 141 25 1434 25 766 11
Region 6: (AR, LA, NM, OK, TX) 1544 12 5 1 776 14 763 11
Region 7:(IA, KS, MO, NE) 670 5 1 0 134 2 535 8
Region 8:(CO, MT, ND, SD, UT, WY) 391 3 75 13 153 3 163 2
Region 9:(AZ, CA, HI, NV) 1705 13 129 23 585 10 991 15
Region 10 (AK, ID, OR, WA) 768 6 46 8 3 0 719 11
FACT and Core Clinical 
Trial Network             
(32 Centers)
Transplant Year
Gender
All 
Centers by 
Department of 
Health and 
Human Services 
Regions
FACT 
Certification 
Only             
(106 Centers)
Patient Race
Patient Age at 
Transplant
No FACT 
Certification 
(24 Centers) 
Center Transplant 
Volume 
Patient Karnofsky 
Performance 
Status Score at 
Transplant
HLA Matching 
Related/Unrelated 
Donor
Coexisting 
Disease
Disease Group
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Table 7: Relative Odds of HLA Mismatch among HLA Mismatched HCT Patients (2008-2010) 
OR
FACT Status
No FACT Certif ication
FACT Only Certif ication 1.225 0.938 1.6
FACT/CTN Certif ication 1.433 1.081 1.901
Transplant Year
2008
2009 1.065 0.949 1.194
2010 0.894 0.795 1.004
Gender
Male
Female 0.956 0.869 1.051
Race
Non-Hispanic White 
Hispanic 1.509 1.273 1.788
Black/African American 3.158 2.666 3.741
Other/Multiple Race/Unknow n 1.36 1.098 1.684
Age Categories
18 to 29
30 to 39 0.948 0.792 1.136
40 to 49 0.776 0.657 0.915
50 to 59 0.64 0.545 0.751
60 to 69 0.726 0.613 0.859
≥80 0.86 0.612 1.208
Patient Karnofsky Performance Status Score at Transplant
90-100
≤80 1.089 0.984 1.206
Missing 1.007 0.79 1.283
Coexisting Disease
Absent or Missing 
Present 1.169 1.055 1.295
Disease Group
Acute Myelogenous Leukemia & Myelodysplastic Disorders 
Acute Lymphoblastic Leukemia 0.83 0.709 0.968
Other Leukemia & Myeloproliferative Syndromes 0.89 0.766 1.023
Non-Hodgkin lymphoma (NHL) & Hodgkin Lymphoma (HL) 0.95 0.835 1.081
Other Malignancy 0.737 0.575 0.945
Severe Aplastic Anemia 0.666 0.482 0.919
Other Non-Malignant Disease 0.88 0.54 1.45
High Volume Quartile Indicator
Quartile I Volume Centers (1-5 Transplants)
Quartile II Volume Centers (6-44 Transplants) 0.97 0.55 1.71
Quartile III Volume Centers (45-107 Transplants) 1.05 0.60 1.82
Quartile IV Volume Centers (108-713 Transplants) 1.106 0.636 1.921
Centers by Department of Health and Human Services Regions
Region 1: (CT, ME, MA, NH, RI, & VT)
Region 2: (NJ, NY) 1.426 1.13 1.799
Region 3: (DE, DC, MD, PA, VA, WV) 2.119 1.705 2.632
Region 4: (AL, FL, GA, KY, MS, NC, SC, TN) 1.092 0.881 1.355
Region 5: (IL, IN, MI, MN, OH, WI) 0.985 0.792 1.224
Region 6: (AR, LA, NM, OK, TX) 0.912 0.724 1.151
Region 7:(IA, KS, MO, NE) 1.295 0.994 1.688
Region 8:(CO, MT, ND, SD, UT, WY) 0.799 0.553 1.154
Region 9:(AZ, CA, HI, NV) 1.268 1.017 1.58
Region 10 (AK, ID, OR, WA) 1.145 0.88 1.491
REF
REF
REF
REF
REF
Table 2. Relative Odds of HLA M ismatch among Related or Unrelated Transplant Recipieints 2008-2010
Related/Unrelated HLA M ismatch
95% CI
REF
REF
REF
REF
REF
 
*Significant values <0.05 Bolded 
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Table 8: Factors Associated with 3 Year Relative Hazard of Death Among HCT Patients, 
Cox Proportional Hazard models, Hazard Ratio, 95% CI 
 
  Cox Model Related/Unrelated  Mismatched  
  Hazard Ratio 95% CI P Value 
HLA Match Category by FACT Status  
No FACT Status/ Matched  REF 
FACT Only Status/ Matched  1.138 0.987 1.311 0.0757 
FACT/CTN Certification/ Matched 1.008 0.868 1.172 0.9146 
No FACT Status/ Mismatched 2.058 1.527 2.772 <.0001 
FACT Only Status/ Mismatched 1.713 1.462 2.007 <.0001 
FACT/CTN Certification/ Mismatched 1.266 1.073 1.495 0.0052 
Transplant Year  
2008 REF 
2009 0.998 0.939 1.06 0.9451 
2010 0.992 0.929 1.059 0.8031 
Gender  
Male  REF 
Female 0.929 0.883 0.978 0.0046 
Patient Race  
Non-Hispanic White  REF 
Hispanic  1.056 0.956 1.166 0.2815 
Black/African American 1.149 1.031 1.281 0.0119 
Other/Multiple Race/Unknown 1.001 0.882 1.136 0.9844 
Patient Age Category  
18-29 REF 
30-39 1.04 0.929 1.164 0.4953 
40-49 1.21 1.096 1.337 0.0002 
50-59 1.32 1.201 1.451 <.0001 
60-69 1.516 1.374 1.671 <.0001 
≥80 1.682 1.406 2.012 <.0001 
Patient Karnofsky Performance Status Score 
at transplant 
 
90-100 REF 
≤80 1.496 1.419 1.578 <.0001 
Missing 1.26 1.109 1.431 0.0004 
Coexisting Disease  
Absent or Missing REF 
Present 1.188 1.124 1.255 <.0001 
Disease Group  
Acute Myelogenous Leukemia & 
Myelodysplastic Disorders  
REF 
Acute Lymphoblastic Leukemia 1.027 0.945 1.115 0.5314 
Other Leukemia & Myeloproliferative 
Syndromes 0.776 0.717 0.839 <.0001 
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Non-Hodgkin lymphoma (NHL) & Hodgkin 
Lymphoma (HL)  0.837 0.78 0.899 <.0001 
Other Malignancy 0.948 0.842 1.068 0.381 
Severe Aplastic Anemia 0.574 0.467 0.706 <.0001 
Other Non-Malignant Disease 0.676 0.471 0.969 0.0333 
  Cox Model Related/Unrelated  Mismatched  
 Centers by Department of Health and Human 
Services Regions 
Hazard Ratio 95% CI P Value 
Region 1: (CT, ME, MA, NH, RI, & VT) REF 
Region 2: (NJ, NY)  1.089 0.963 1.231 0.172 
Region 3: (DE, DC, MD, PA, VA, WV) 
1.127 1.001 1.269 0.0483 
Region 4: (AL, FL, GA, KY, MS, NC, SC, TN) 1.118 1.001 1.248 0.0478 
Region 5: (IL, IN, MI, MN, OH, WI) 1.06 0.949 1.184 0.3004 
Region 6: (AR, LA, NM, OK, TX) 1.132 1.009 1.271 0.0354 
Region 7:(IA, KS, MO, NE)  1.322 1.152 1.516 <.0001 
Region 8:(CO, MT, ND, SD, UT, WY)  1.001 0.842 1.191 0.9887 
Region 9:(AZ, CA, HI, NV)  1.059 0.942 1.191 0.3374 
Region 10 (AK, ID, OR, WA) 1.127 0.978 1.297 0.0977 
High Volume Quartile Indicator  
Quartile I Volume Centers (1-5 Transplants) REF 
Quartile II Volume Centers (6-44 Transplants) 1.23 0.878 1.721 0.2283 
Quartile III Volume Centers (45-107 
Transplants)  1.032 0.743 1.435 0.8495 
Quartile IV Volume Centers (108-713 
Transplants)  0.918 0.66 1.277 0.612 
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Figure 6A: Percentages of Related and Unrelated HCT by FACT Status (2008-2010) 
 
 
 
Figure 6B: Percentages of Related/Unrelated Matched or Mismatched  HCT by FACT Status (2008-
2010) 
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Figure 7A: Kaplan Meier: All Adult HCT Survival by FACT Status: 2008-2010 
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 75 
 
 
Figure 7B: Mismatched Related and Unrelated Adult HCT Survival by FACT Status: 2008-2010 
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Figure 7C: Matched Related and Unrelated Adult HCT Survival by FACT Status: 2008-2010  
 
 
 
 
 
 
 
 
FACT Only Center Status 
FACT/CTN Center Status 
Non-FACT 
Center 
Status 
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Chapter 5: Geographic Inequality or Advantage: The Impact of Distance to 
Transplant Center on Outcomes after Unrelated Donor HCT in the United States 
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Background: Hematopoietic cell transplantation (HCT) is the transplantation of stem 
cells from a donor and an effective treatment for many hematologic malignancies. The 
complexity of HCT requires lengthy specialized care that could put patients residing in 
distant locations at a distinct disadvantage compared to patients that resided closer to 
their HCT center. We sought to evaluate the differences in survival and post-transplant 
complications {chronic graft-versus-host disease (cGvHD)} among HCT patients by 
distance to center. 
Methods: To evaluate the association between distance to transplant center and HCT 
survival, we studied all patients reported to the Center for International Blood and 
Marrow Transplant Research (CIBTMR) who received transplant between January 1, 
2000-December 31, 2009 data. Using Google Maps we calculated driving distance in 
minutes from patient zip code to transplant center. We categorized patients into distance 
quartiles and bifurcated our upper quartile to create a fifth category of patients who had 
travel times >6 hours.  Utilizing our distance stratification we examined the association 
between distance category and hazard of death and cGvHD using Cox Proportional 
Hazard modeling.  
Results: There were 10,068 HCT recipients at 130 transplant centers from 2000-2009 in 
the cohort. Median driving distance was 65 minutes (range 2 minutes- 20,820 minutes). 
Our patient cohort was predominately older (over the age of 40) (66%) and male (58%). 
Over time, patients decreased their long distance travel for HCT from a median time of 
78 minutes in 2000 to 60 minutes in 2009. Unadjusted Kaplan Meier mortality estimates 
showed differences between 9 year overall mortality among patients in our fifth distance 
category and all other distance categories. After adjusting for patient and center 
characteristics we found that distance from the transplant center was not significantly 
associated with overall survival or disease free survival (adjusted hazard ratio (HR): 
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.975; 95% Confidence Interval (.884-1.075) Distance category 361-20,820 minutes vs. 2-
32 minutes). 
Conclusions: Our findings suggest that patients accessing HCT from longer distances 
need not necessarily expect inferior outcomes.  This was especially apparent for more 
complex HLA mismatched patients. For payers and policy makers our findings indicate 
that, if sufficient post-transplant care is provided, there is no clear benefit to restrict the 
performance of HCT to the closest available center. 
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Background 
Hematopoietic cell transplantation (HCT) is the transplantation of stem cells from 
a donor and is an effective treatment for many hematologic malignancies. The 
complexity of HCT requires lengthy specialized care and that post-transplant recovery 
necessitates that the transplant recipient remain in close proximity to their center for 
potential treatment.86-88  There are two ways in which distance to HCT could impact 
outcomes. Distance to facility could be important for expediting the process that leads to 
the donor recipient match, diagnostic screening and for post-transplant care. Patients 
who travel long distances or who opt to receive recommended post-transplant screening 
from providers who are unfamiliar with treatment plans may receive suboptimal care 
from providers that lack the advanced techniques necessary for HCT patients.88 
Conversely, it is possible that patients that travel longer distances receive more vigilant 
specialty care prior to discharge and are ultimately healthier at discharge prior to post-
transplant travel.   
Health services research has shown that patients in rural areas or patients that 
have to travel considerably greater distances than their urban counterparts to access 
specialized care detrimentally impacts healthcare access and utilization.89-92 Length of 
stay for HCT is particularly longer than most other conditions, such as emergent care, 
elective hospital care, primary care and other cancers. Geographical location 
(urban/rural) and their proximity to transplant centers have been hypothesized to be a 
predictor of successful outcomes and mitigate post-transplant complications such as 
graph versus host disease (GvHD). Yet, the research documenting the relationship 
between survival and distance is sparse.  A recent study by Abou-Nassar et al. analyzed 
a cohort of adult patients who underwent allogeneic HCT at the Dana-Farber/Brigham 
and Women’s Cancer Center between 1996 and 2009 and who resided within 6 hours 
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driving time of the institution. 88 They found that overall survival (OS) for patients 
stratified by driving time quartile after HCT was similar in the first year but worse after 1 
year in patients in the top quartile (>160 minutes driving time). 88 In a retrospective 
cohort of patients undergoing HCT in Nebraska, patients from rural areas undergoing 
autologous stem cell transplantation were found to have inferior results compared to 
patients from urban areas.34 Research by Loberiza and colleagues found that results 
were not inferior for rural patients and that there was no urban/rural distinction.93    
We sought to use national U.S. data from 130 centers to evaluate the differences 
in survival and post-transplant complications (GvHD) among HCT patients by distance to 
center. 
Methods 
Data Source and Patients 
The Center for International Blood and Marrow Transplant Research (CIBMTR) is 
a research affiliation of the International Bone Marrow Transplant Registry, Autologous 
Blood and Marrow Transplant Registry, and National Marrow Donor Program (NMDP) 
that was established in 2004. CIBMTR is comprised of a voluntary working group of 
more than 450 transplantation centers worldwide that contribute detailed data on 
consecutive HCT to a Statistical Center at the Medical College of Wisconsin in 
Milwaukee, WI and the NMDP Coordinating Center in Minneapolis, MN. In addition, the 
CIBMTR holds the contract for the Stem Cell Therapeutic Outcomes Database part of 
the CW Bill Young Transplantation Program from the Human Resources and Services 
Administration; as a part of this Program, all transplant centers in the US are mandated 
to report clinical outcomes data for allogeneic HCT to the CIBMTR. Data are collected 
before transplant, 100 days and 6 months after transplant, and annually thereafter or 
until death. Computerized checks for discrepancies, physician review of submitted data 
and on-site audits of participating centers ensure data quality. We obtained a de-
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identified dataset from CIBTMR. Our study was deemed exempt from review by the 
Human Subjects Committee of the University of Minnesota’s Institutional Review Board.  
Patient Variables Utilized 
We included transplant recipients 18 years or older who received transplants 
between January 1, 2000 through December 31, 2009 and were reported to the 
CIBTMR. We included patients who received peripheral blood stem cells or bone 
marrow graft from HLA-matched or mismatched unrelated donors. All diagnoses were 
included.  
We utilized patient race, gender, the HLA match status of the patient, coexisting 
disease, Karnofsky score, and chronic GvHD (cGvHD) status. CIBMTR reports both the 
incidence of cGvHD and when it occurs. CIBMTR censored patients that died without 
cGvHD or second transplant (Competing risk) or were alive or had second transplant 
with no cGvHD event. The Karnofsky performance status is used to determine the 
functional status of a recipient and can range from 0-100. A Karnofsky performance 
score of 90-100 categorizes patients with the ability to carry on normal activity and no 
special care is needed. Karnofsky performance score was considered by CIBTMR as a 
dichotomous variable of 90-100 and ≤ 80. Coexisting disease is a binary category of 
diseases collected by CIBMTR. CIBMTR codes HCT patients with any of 18 
comorbidities as coexisting disease present.  
The HLA match status of donors describes the degree of immunologic similarity 
between recipients and donors.  We categorized patients as HLA matched or 
mismatched HCTs. We excluded patients with missing HLA match information (N=718) 
Length of stay (LOS) and 100 day survival has typically been used by literature 
as important cutoff for HCT and survival outcomes.88, 94 Although CIBTMR does not 
collect LOS from transplant centers we used 100 day survival as a proxy for LOS to 
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determine if the difference in survival probability by distance category persisted for 
patients with 100 day post-transplant survival. 
In order to link patient zip code with median household income, we used the 
most recent 2007-2011 United States Census Bureau American Community Survey 
(ACS), a statistical survey that samples a small percentage of the population every year, 
to extract median household income by ZIP code tabulation areas.95 The 5-Digit ZIP 
code tabulation areas (ZCTA) geographic levels are generalized area representations of 
United States Postal Service (USPS) ZIP Code service areas. 96 In most instances, an 
address ZIP code will also be the ZCTA in which that address falls.97 However, an 
address's ZIP code does not consistently match the ZCTA it falls into and conversely 
that ZIP code may not match the ZCTA (N=178 patients).   
Distance Defined 
Using Google Maps we calculated driving distance in minutes from patient zip 
code to transplant center zip code. 98 This approach produced comparable estimates 
with the SAS 9.3 ZIPCITY function. 99 We divided our cohort into quartiles and 
subdivided the upper quartile into a group of patients that resided more than 6 hours 
driving time from the transplant center.  Patients with invalid zip codes, foreign zip codes 
and patient zip codes that matched identically with transplant center zip codes were 
excluded (N=843 patients, 7% of total). 
Transplant Center Characteristics  
We also utilized several transplant center characteristics in our models, including 
center volume (quartiles), The Foundation for the Accreditation of Cellular Therapy 
center (FACT), Core Blood and Marrow Transplant Clinical Trial Network (CTN) status 
and center geographic location (Department of Health and Human Services (HHS) 
regions). Based on the literature, we found benefit in categorizing centers with non-
FACT, FACT Only or FACT/CTN status. 100  
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Statistical Analysis 
The primary objective of this retrospective study was to examine if geographic 
proximity affects overall survival (OS) of HCT patients from 2000-2009 and post-
transplant complications such as cGvHD. We compared the relationship between 
distance categories using chi-square tests. Overall survival (OS) and disease-free 
survival (DFS) were calculated using the Kaplan-Meier method with significance testing 
using log rank tests. OS was defined as the time from stem cell infusion to death from 
any cause. Patients lost to follow-up were censored at the date last known alive. DFS 
was defined as the time from stem cell infusion to disease relapse, progression, or death 
from any cause. We evaluated differences in distance categories, HLA match status, 
cGvHD and patient characteristics across all years of transplantation.  In order to 
capture the interaction between distance travelled and patient complexity we created a 
distance to facility by HLA match category variable. 
After assessing this unadjusted relationship we utilized multivariable Cox 
proportional hazards models to evaluate the association between distance categories 
and death. We then used multivariate logistic regression to determine the odds of 
cGvHD occurrence. 
In all models, we performed several sensitivity analyses such as the removal of 
non-statistically significant factors and use of stratification to ensure that the observed 
effects were not a product of our modeling decisions (appendix 12-17).  We examined 
the impact of alternate categories to confirm that our findings were not a product of our 
distance categories (appendix 12-14). Under all assumptions, conclusions remain 
unchanged. SAS version 9.3 (SAS Institute) was used for all analyses. P values were 2 
sided with a level of significance of ≤.05.  
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Results 
Our final cohort included 10,068 transplants conducted in 130 centers between 
January 1, 2000 through December 31, 2009. Median driving distance was 65 minutes 
(range 2 minutes- 20,820 minutes). Our patient cohort was predominately older (over the 
age of 40) (66%) and male (58%). Over time, patients decreased their long distance 
travel for HCT from a median time of 78 minutes in 2000 to 60 minutes in 2009.  
Nearly half of the patient cohort consisted of HLA matched unrelated HCTs 
(N=6,291; 46%) and the remainder were mismatched HCTs (3,147; 54%). There was no 
apparent difference in travel time for mismatched HCT. The median travel time for HCT 
mismatched patients was 60 minutes and the median time for matched patients was 68 
minutes. Over 31% of our cohort was unable to carry on normal activity with no special 
care needed prior to transplantation (Karnofsky scoring ≤80) and 61% of our population 
was classified by CIBMTR as having coexisting disease prior to HCT. We observed 
variation in median travel time by disease group. Median travel time for AML and MDS 
was 65 minutes, 59 minutes for ALL and 77 minutes for CML, other Leukemia and MPS.  
There was a strong correlation between income and travel time. Of the 2,482 
patients in the upper quartile of median household income ($73,258-$242,188) only 30% 
travelled beyond the median driving distance for receipt of HCT (64 minutes). Of patients 
in the lower quartile of median household income ($10,055-$43,796), 68% travelled 
beyond 64 minutes for their transplants.  
{Table 9A-91B Here} 
 
Association between Driving Distance Category and Mortality 
Unadjusted Kaplan Meier mortality estimates showed differences between 9 year 
overall mortality among patients in our fifth distance category and all other distance 
categories. Although patients in the first four categories had similar OS, our fifth distance 
category showed higher survival than our other distance categories. In order to observe 
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whether survival differs between groups once patients are discharged from the 
transplant center we used 100 day survival as a proxy for LOS and excluded patients 
with ≤100 days of survival. After this exclusion, we observed similar patterns in our 
unadjusted Kaplan Meier mortality estimates when we plotted curves with patients living 
>6 hours away vs. all others.     
{Figure 8A and 8B Here} 
However, after adjusting for patient and center characteristics we found that our 
upper quartile distance groups were not significantly associated with lower relative 
hazard of death (adjusted hazard ratio (HR): .975; 95% Confidence Interval (.884-1.075) 
Distance category 361-20,820 minutes vs. 2-32 minutes). 
{Table 10 Here} 
Earlier year of transplant (2009 versus 2000), gender (female versus male), 
Karnofsky performance stratus score <80, other malignancies, and Severe Aplastic 
Anemia (versus AML and MDS) were all associated with lower 9 year relative hazard of 
death (p<0.05 for all). The results of our DFS models showed similar patterns. Namely, 
patients that lived 6 hours or more away from their transplant centers had lower 9 year 
hazard of death or relapse versus all other distance categories.  
Association between Driving Distance Category and HLA Match and Mismatch HCT 
When we grouped our distance categories by HLA matched and mismatched 
HCT and plotted Kaplan Meier curves we observed an advantage for mismatched HLA 
unrelated patients living >6 hours away vs. all others. We did not observe this long 
distance travel advantage when we grouped our distance categories by HLA matched.  
{Figure 9A and 9B Here} 
After adjusting for patient and center characteristics we found that the more 
complex,  HLA mismatched patients that resided 6 hours or more from the HCT center 
were significantly associated with lower relative hazard of death (adjusted hazard ratio 
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(HR): .79; 95% Confidence Interval (.67-.95) Distance category 361-20,820 minutes vs. 
2-32 minutes).  
{Table 11 Here} 
Earlier year of transplant (2009 versus 2000), gender (female versus male) 
Karnofsky performance stratus score <80, disease groups (other leukemia and MPS, 
other malignancies and SAA versus AML and MDS) were all associated with lower 9 
year relative hazard of death (p<0.05 for all) for the HLA mismatched cohort.  
Association between Driving Distance Category and Post-Transplant Complications: 
cGvHD 
Unadjusted Kaplan Meier estimates showed only small differences between 
cGvHD probability among patients in our fifth distance category and all other distance 
categories. Although patients in the first, second, third and fourth categories had similar 
cGvHD after 1 year, our fifth distance category showed a lower probability of cGvHD 
diagnosis before 1 year (78% for patients that travelled >6 hours compared to 93% for 
patients travelling <6 hours).  
{Figure 10 Here} 
After adjusting for patient and center characteristics we found that HLA 
mismatched patients that travelled more than 6 hours were significantly associated with 
higher odds of cGvHD (adjusted OR: 1.545; Confidence Interval (1.19- 2.01) Distance 
category 4 (150-360 minutes)  vs. 1 (2-32 minutes)). Less complex, HLA matched 
patients showed lower but not significant odds of cGvHD.   
{Table 12 Here} 
Other covariates that were associated with higher odds of cGvHD estimates 
included  year of transplant (2003+ versus 2000) and patient Karnofsky performance 
status score at transplant (p<0.05 for all).  
 
 
 88 
 
Discussion 
The last several decades has witnessed a remarkable expansion of HCT use 
both in the U.S. and globally. Although HCT centers continue to explore new clinical 
successes we observed that patients are decreasing their long distance travel for HCT. 
Our data does not allow us to explain this decline in travel. However, we suspect that in 
addition to the increase in the number of HCT centers within markets, the decline in 
travel for HCT can also partially be attributed to a confluence of events including, more 
restrictive managed care plans and patient and provider caution at increased travel. 
Despite potential motivations that would restrict travel for HCT, our findings suggest that 
long distance travel to HCT center is not a cause of inferior results. Moreover, the 
potential precautions that are taken with long distance travelling for HCT may produce 
advantages that modestly improve OS and cGvHD outcomes for patients that travel 6 
hours or more.   
We observed the clearest distance benefit for the most complex HLA 
mismatched patients living 6 or more hours from their transplant center. This benefit was 
not evident for HLA matched patients. We did not observe significant differences 
between driving distance and median household income. These results imply that in 
addition to the precautions taken at the treatment center with long distance patients 
there is additional caution taken for complex HCT that may include prolonged LOS. The 
advantage for complex patients persisted for the entire study period implying that post-
transplant care has improved beyond the HCT center of origin. Furthermore, patients 
living 6 or more hours from their transplant center might intensify the caution taken by 
provider and request a delay in their discharge.  
Our findings have important policy implications for patients, providers, payers 
and policy makers. Patients accessing HCT from longer distances need not necessarily 
expect inferior outcomes. This expectation is applicable for complex HLA mismatched 
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and simpler HLA matched patients. For providers, the precautions taken for long 
distance patients seem to be not only justified but necessary for OS and the prevention 
of GvHD occurrence. It has previously been hypothesized that the patients in upper 
distance categories have limited access to post-HCT specific care and are more prone 
to HCT complications such as infections and GVHD that should ideally be managed by 
providers with HCT specific expertise. However, based on our findings it would appear 
that HCT centers are able to ensure the success of transplants for patients who reside 
long distances from transplant centers perhaps by effectively disseminating advanced 
post-transplant care techniques to non-specialized clinicians providing post-transplant 
care.  For payers and policy makers our findings indicate that, if sufficient post-transplant 
care is provided, there is no risk to patients who need to travel to receive care. However, 
other work by Marmor et al. suggests that while low risk patients need not travel for HCT 
and can expect to receive comparable HCT care at low risk centers, there is an 
advantage for complex patients to travel to centers of excellence for HCT. 100 Indeed, we 
did observe a driving distance advantage for our complex patients.  
Although there is an extensive literature that observes distinct disparities in 
cancer outcomes and survival based on the distance to the treatment center25-32, 101, few 
have focused on nationwide U.S. HCT. Previous findings of Abou-Nassar et al. showed 
inferior outcomes for patients that resided 160-360 minutes driving time from the Dana-
Farber/Brigham and Women’s Cancer Center.88 In a study at the University of Nebraska 
Medical Center between 1983 and 2004, primary area of residence was used to classify 
patients as either rural or urban.  Results were mixed. Among the autologous HCT 
patients, those from rural areas were found to have a higher mortality versus patients 
from urban areas but this difference was not evident for patients undergoing allogeneic 
HCT.34 A registry study from Canada found that there were no significant survival 
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differences between urban and rural patients undergoing autologous or allogeneic 
HCT.35 
Our study builds upon previous studies examining the implications of distance on 
overall HCT survival and complications.  Our analysis moves beyond a rural versus 
urban distinction.  Additionally, in contrast to Abou-Nassar, we included patients residing 
> 6 hours away from their transplant centers in our analyses. 88 We recognize that 
patients residing 6 or more hours away from their HCT center would often use other 
modes of transportation to reduce their travel time and facilitate access that could also 
contribute to superior transplant results. Our results persisted even after restricting our 
sample to patients that had survived >100 days post HCT. 
Although our study provides further insight into the relationship between patient 
distance to HCT center and post-transplant outcomes we acknowledge several data 
related limitations. CIBTMR did not provide detailed post-transplant care including the 
frequency of follow up care visits and the types of providers that were available to 
patients after HCT. However, even after we restricted our cohort to >100 days survival 
our results persisted suggesting that some aspect of clinical decision making is different 
for long distance patients.  Our observed differences in OS by driving time did not 
appear to be directly attributable to measurable differences in patient baseline 
characteristics that the literature has previously established as important predictors of 
risk such as age, Karnofsky performance status, HLA matching category and coexisting 
disease.7-9, 13-18 We cannot exclude possible confounding by unmeasured 
socioeconomic variables and reporting error due to our use of the median income 2007-
2011 ACS variables. However, median household income did not appear to be directly 
attributable to survival and GvHD complications.  Lastly, our analysis was restricted to 
unrelated transplants. We do not know if our results are generalizable to related 
 91 
 
transplants. Despite these limitations we found significant distinctions between our 
distance categories that indicate that long distance HCT patients may indeed expect 
comparable survival and outcomes results compared to other patients.  
Although our findings suggest that long distance HCT offer modestly superior 
results versus other patients that reside closer to their treatment center, the broader 
relationship between a patients’ distance and survival and complications rate remains 
complex. A deeper understanding of the causal mechanisms involved is required to find 
specific factors that could be introduced to all centers to improve outcomes for all long 
distance patients. While our work begins to distinguish  differences in patient distance, 
our results suggest the need for additional research using longitudinal data and 
corresponding methods to investigate the factors that more broadly predict the 
characteristics of superior results for long distance related and unrelated HCT patients 
and ultimately improve survival for all patients regardless of distance and complexity.  
 
 
 
 
 
 
 
 
 
 92 
 
Table 9A: Basic Characteristics of Unrelated Transplant Recipients by Driving Distance Category (2000-2009)  
 
Time 
Distance              
(2-32 min) 
Time 
Distance  
(33-64 
min) 
Time Distance  
(65-149 min) 
Time Distance  
(150-360 min) 
Time Distance     
(361-20,820 min) 
P-
Value 
N % N % N % N % N % 
    2489 25 2512 25 2573 26 1425 14 1069 11 
Transplant Year  
  <.0001 
2000 157 24 132 20 162 24 105 16 107 16 
  
2001 146 23 163 25 158 25 80 12 97 15 
2002 186 24 195 25 185 24 104 14 100 13 
2003 227 24 218 23 255 27 116 12 117 13 
2004 282 26 260 24 261 24 163 15 128 12 
2005 297 25 289 24 294 25 188 16 112 9 
2006 315 24 338 26 350 26 195 15 124 9 
2007 361 26 371 26 367 26 177 13 137 10 
2008 263 25 277 26 280 26 159 15 83 8 
2009 255 26 269 27 261 26 138 14 64 6 
Gender 
  
  
  0.2517 
Female 1096 26 1040 25 1078 25 593 14 435 10   
Male  1393 24 1472 25 1495 26 832 14 634 11   
Patient Race   
                      <.0001 
Non-Hispanic White  1986 23 2198 25 2344 27 1284 15 952 11   
Hispanic  193 35 142 26 88 16 82 15 40 7   
Black/African American 185 46 74 18 86 21 32 8 27 7   
Other/Multiple Race/Unknown 125 35 98 28 55 15 27 8 50 14   
Recipient Age at Transplant  
  0.0013 
18 to 29 485 27 428 24 482 27 256 14 153 8   
30 to 39 396 25 381 24 394 25 234 15 162 10   
40 to 49 532 24 516 23 617 28 318 14 
241 11 
  
50 to 59 658 23 730 26 716 25 395 14 
314 11 
  
60 to 64 266 26 280 27 230 22 133 13 119 12   
65+ 152 24 177 28 134 21 89 14 
80 13 
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Recipient Karnofsky Performance Status score at transplant  
  <.0001 
90-100 1532 25 1525 25 1552 26 841 14 591 10   
10-80 774 25 787 25 832 26 454 14 305 10   
Missing  183 21 200 23 189 22 130 15 173 20   
Coexisting Disease    
      0.0949 
Absent or Missing  1001 26 924 24 980 25 571 15 418 11   
Present 1488 24 1588 26 1593 26 854 14 651 11   
Disease Group 
                      <.0001 
Acute Myelogenous Leukemia & 
Myelodysplastic Disorders 1281 25 1289 25 1353 26 716 14 506 10 
  
Acute Lymphoblastic Leukemia 367 26 388 27 355 25 187 13 123 9 
Other Leukemia & Myeloproliferative 
Syndromes 448 22 461 23 490 24 336 17 286 14 
Non-Hodgkin lymphoma (NHL) & Hodgkin 
Lymphoma (HL)  263 26 263 26 264 26 134 13 91 9 
Other Malignancy 33 30 22 20 22 20 12 11 20 18 
Severe Aplastic Anemia 83 28 78 27 75 26 35 12 23 8 
Other Non-Malignant Disease 14 22 11 17 14 22 5 8 20 31 
HLA Matching  Donor   
    <.0001 
Matched 1638 24 1716 25 1828 26 965 14 774 11   
Mismatched 851 27 796 25 745 24 460 15 295 9   
Median Household Income Quartile Categories  
  <.0001 
Quartile 1 ($10,055-$43,796) 502 20 293 12 842 34 555 23 268 11   
Quartile 2 ($43,797-$55,702) 531 21 497 20 723 29 470 19 262 11   
 Quartile 3 ($55,703-$73,257) 675 27 728 30 578 23 238 10 246 10   
 Quartile 4 ($73,258-$242,188) 748 30 962 39 378 15 135 5 259 10   
Missing  33 19 32 18 52 29 27 15 34 19   
Centers by Department of Health and Human Services Regions  
  <.0001 
Region 1: (CT, ME, MA, NH, RI, & VT) 188 24 234 30 198 25 131 17 33 4   
Region 2: (NJ, NY)  360 43 238 29 172 21 48 6 11 1   
Region 3: (DE, DC, MD, PA, VA, WV) 239 26 314 34 289 31 66 7 13 1   
Region 4: (AL, FL, GA, KY, MS, NC, SC, TN) 209 16 245 19 484 38 294 23 51 4   
Region 5: (IL, IN, MI, MN, OH, WI) 529 27 529 27 535 28 238 12 108 6   
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Region 6: (AR, LA, NM, OK, TX) 301 22 255 19 232 17 248 18 331 24   
Region 7:(IA, KS, MO, NE)  157 26 129 21 191 31 121 20 14 2   
Region 8:(CO, MT, ND, SD, UT, WY)  63 26 73 30 48 20 44 18 14 6   
Region 9:(AZ, CA, HI, NV)  265 23 380 33 317 28 117 10 69 6   
Region 10 (AK, ID, OR, WA) 178 19 115 12 107 11 118 13 425 45   
High Volume Quartile Indicator   
                      <.0001 
Quartile I Volume Centers (1-9 
Transplants) 35 30 31 27 32 28 14 12 4 3   
Quartile II Volume Centers (10-48 
Transplants) 336 38 236 27 159 18 85 10 65 7   
Quartile III Volume Centers (49-93 
Transplants)  631 30 576 27 617 29 240 11 70 3   
Quartile IV Volume Centers (94-681 
Transplants)  1487 21 1669 24 1765 25 1086 16 930 13   
FACT Status  
  <.0001 
No FACT Certification 103 38 49 18 50 18 31 11 40 15   
FACT Only Certification 1377 31 1257 28 1155 26 484 11 174 4   
FACT/CTN Certification 1009 19 1206 23 1368 26 910 17 855 16   
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Table 9B: Total Basic Characteristics of Unrelated Transplant Recipients by 
Driving Distance Category (2000-2009) 
 N % 
Total  10,068 100 
Transplant Year  
2000 663 7 
2001 644 6 
2002 770 8 
2003 933 9 
2004 1094 11 
2005 1180 12 
2006 1322 13 
2007 1413 14 
2008 1062 11 
2009 987 10 
Gender  
Female 4242 42 
Male  5826 58 
Patient Race 
Non-Hispanic White 8764 87 
Hispanic  545 5 
Black/African American 404 4 
Other/Multiple Race/Unknown 355 4 
Patient Age at Transplant  
18 to 29 1804 18 
30 to 39 1567 16 
40 to 49 2224 22 
50 to 59 2813 28 
60 to 64 1028 10 
65+ 632 6 
Recipient Karnofsky Performance Status score at transplant  
90-100 6041 60 
10-80 3152 31 
Missing  875 9 
Coexisting Disease  
Absent or Missing  3894 39 
Present 6174 61 
Disease Groups   
Acute Myelogenous Leukemia & 
Myelodysplastic Disorders 
5145 51 
Acute Lymphoblastic Leukemia 1420 14 
Other Leukemia & Myeloproliferative 
Syndromes 
2021 20 
Non-Hodgkin lymphoma (NHL) & 
Hodgkin Lymphoma (HL)  
1015 10 
Other Malignancy 109 1 
Severe Aplastic Anemia 294 3 
Other Non-Malignant Disease 64 1 
HLA Matching  Donor    
Matched 6921 69 
Mismatched 3147 31 
Median Household Income Quartile Categories  
Quartile 1 ($10,055-$43,796) 2460 24 
Quartile 2 ($43,797-$55,702) 2483 25 
 Quartile 3 ($55,703-$73,257) 2465 24 
 Quartile 4 ($73,258-$242,188) 2482 25 
Missing  
178 2 
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Centers by Department of Health and Human Services Regions  
Region 1: (CT, ME, MA, NH, RI, & VT) 784 8 
Region 2: (NJ, NY)  829 8 
Region 3: (DE, DC, MD, PA, VA, WV) 921 9 
Region 4: (AL, FL, GA, KY, MS, NC, 
SC, TN) 
1283 13 
Region 5: (IL, IN, MI, MN, OH, WI) 1939 19 
Region 6: (AR, LA, NM, OK, TX) 1367 14 
Region 7:(IA, KS, MO, NE)  612 6 
Region 8:(CO, MT, ND, SD, UT, WY)   242 2 
Region 9:(AZ, CA, HI, NV)  1148 11 
Region 10 (AK, ID, OR, WA) 943 9 
High Volume Quartile Indicator      
Quartile I Volume Centers (1-9 
Transplants) 
116 1 
Quartile II Volume Centers (10-48 
Transplants) 
881 9 
Quartile III Volume Centers (49-93 
Transplants)  
2134 21 
Quartile IV Volume Centers (94-681 
Transplants)  
6937 69 
FACT Status  
No FACT Certification 273 2.7 
FACT Only Certification 4447 44 
FACT/CTN Certification 5348 53 
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Table 10: Factors Associated with 9 Year Relative Hazard of Death (OS and DFS) Among HCT Patients by 
Distance Categories, Cox Proportional Hazard models, Hazard Ratio, 95% CI  
Hazard 
Ratio
P Value
Hazard 
Ratio
P Value
Time Distance (2-32 min)
Time Distance  (33-64 min) 1.024 0.956 1.097 0.499 1.01 0.942 1.083 0.777
Time Distance  (65-149 min) 1.066 0.994 1.143 0.0732 1.056 0.983 1.134 0.1363
Time Distance  (150-360 min) 1.009 0.926 1.099 0.8461 0.982 0.9 1.072 0.6861
Time Distance  (361-20820 min) 0.984 0.897 1.08 0.7326 0.958 0.872 1.054 0.379
2000
2001 0.993 0.875 1.127 0.9101 0.98 0.863 1.114 0.7602
2002 0.924 0.817 1.046 0.2107 0.969 0.856 1.097 0.6218
2003 0.822 0.73 0.927 0.0014 0.829 0.734 0.936 0.0024
2004 0.818 0.728 0.919 0.0007 0.775 0.688 0.873 <.0001
2005 0.709 0.63 0.797 <.0001 0.69 0.612 0.777 <.0001
2006 0.738 0.658 0.828 <.0001 0.752 0.669 0.845 <.0001
2007 0.686 0.611 0.77 <.0001 0.699 0.622 0.784 <.0001
2008 0.616 0.545 0.697 <.0001 0.636 0.562 0.719 <.0001
2009
0.626 0.552 0.711 <.0001
0.633 0.558 0.718 <.0001
Male 
Female 0.907 0.863 0.952 <.0001 0.898 0.854 0.944 <.0001
18 to 29
30 to 39 1.099 1.007 1.199 0.0351 1.078 0.985 1.18 0.1024
40 to 49 1.246 1.148 1.352 <.0001 1.208 1.111 1.313 <.0001
50 to 59 1.399 1.291 1.517 <.0001 1.403 1.292 1.524 <.0001
60 to 64 1.546 1.397 1.71 <.0001 1.578 1.424 1.749 <.0001
65+ 1.665 1.482 1.87 <.0001 1.666 1.48 1.875 <.0001
Non Hispanic White  
Hispanic 1.15 1.03 1.284 0.0132 1.068 0.951 1.2 0.2676
Black/African American 1.315 1.166 1.482 <.0001 1.257 1.109 1.425 0.0003
Other/Multiple Race/Unknown 1.089 0.953 1.244 0.2095 1.057 0.918 1.216 0.4418
Acute Myelogenous Leukemia & 
Myelodysplastic Disorders 
Acute Lymphoblastic Leukemia 1.144 1.063 1.231 0.0003 1.134 1.053 1.222 0.0009
Other Leukemia & Myeloproliferative 
Syndromes 0.796 0.746 0.85 <.0001 1.016 0.953 1.083 0.6278
Non-Hodgkin lymphoma (NHL) & Hodgkin 
Lymphoma (HL) 0.925 0.851 1.005 0.0658 1.024 0.936 1.12 0.6057
Other Malignancy 1.303 1.061 1.6 0.0116 1.665 1.287 2.155 0.0001
Severe Aplastic Anemia 0.54 0.449 0.648 <.0001 . . . .
Other Non-Malignant Disease 1.093 0.803 1.488 0.5733 . . . .
Absent or Missing 
Present 1.14 1.08 1.201 <.0001 1.088 1.031 1.148 0.0022
Matched
Mismatched 1.326 1.259 1.397 <.0001 1.224 1.160 1.292 <.0001
90-100
≤80 0.72 0.68 0.758 <.0001 0.727 0.689 0.768 <.0001
Missing 
0.856 0.78 0.941 0.0013 0.884 0.803 0.973 0.0119
Quartile 1 ($10,055-$43,796)
Quartile 2 ($43,797-$55,702) 0.966 0.90 1.034 0.3165 0.954 0.889 1.023 0.1829
 Quartile 3 ($55,703-$73,257) 0.968 0.90 1.039 0.3630 0.972 0.904 1.045 0.4359
 Quartile 4 ($73,258-$242,188) 0.927 0.86 1 0.0492 0.944 0.874 1.019 0.1415
Missing 0.996 0.83 1.2 0.9690 0.959 0.795 1.157 0.6615
No FACT Affiliation 1.191 1.014 1.398 0.0328 1.096 0.928 1.295 0.2782
FACT Only 1.152 1.082 1.227 <.0001 1.094 1.026 1.166 0.0063
FACT/CTN
Region 1: (CT, ME, MA, NH, RI, & VT)
Region 2: (NJ, NY) 1.025 0.904 1.162 0.7005 1.029 0.906 1.169 0.6625
Region 3: (DE, DC, MD, PA, VA, WV) 1.335 1.186 1.502 <.0001 1.39 1.234 1.565 <.0001
Region 4: (AL, FL, GA, KY, MS, NC, SC, TN) 1.194 1.066 1.338 0.0022 1.135 1.012 1.274 0.0311
Region 5: (IL, IN, MI, MN, OH, WI) 1.116 1.004 1.24 0.0419 1.104 0.993 1.228 0.0679
Region 6: (AR, LA, NM, OK, TX) 1.084 0.97 1.212 0.1558 1.121 1.002 1.254 0.0468
Region 7:(IA, KS, MO, NE) 1.152 1.011 1.314 0.0343 1.186 1.039 1.353 0.0112
Region 8:(CO, MT, ND, SD, UT, WY) 1.083 0.903 1.299 0.3891 1.178 0.981 1.414 0.0788
Region 9:(AZ, CA, HI, NV) 1.035 0.921 1.162 0.567 1.088 0.967 1.223 0.1607
Region 10 (AK, ID, OR, WA) 1.008 0.888 1.144 0.9056 1.004 0.883 1.141 0.9513
Quartile I Centers (1-5 Transplants)
Quartile II Centers (6-44 Transplants) 1.093 0.858 1.392 0.473 1.072 0.837 1.373 0.582
Quartile III Centers (45-107 Transplants) 1.059 0.839 1.338 0.6286 1.055 0.831 1.338 0.662
Quartile IV Centers (108-713 Transplants) 0.942 0.746 1.191 0.6192 0.958 0.755 1.216 0.7237
Table 2: Factors Associated with 9 Year Relative Hazard of Death among HCT Patients, Cox Proportional Hazard Models, Hazard Ratio, 95% CI 
REF
REF
Cox Model DFS Unrelated Transplants 
Distance Quartiles 2000-2009 
95% CI
REF
REF
REF
REF
REF
REF
REF
REF
REF
REF
REF
Cox Model OS Unrelated 
Transplants Distance Quartiles 
2000-2009
95% CI
Time Quartile 
Indicator
REF
Transplant Year
REF
Gender
REF
Age Groups
REF
Patient Race
REF
Disease Group
REF
Coexisting 
Disease
REF
HLA Matching  
Donor
REF
Centers by 
Department of 
Health and Human 
Services Regions
REF
Volume Quartile 
Indicator
REF
Pateint Karnofsky 
Performance 
Status Score 
REF
Median 
Household 
Income Quartile 
Categories
REF
FACT/Core 
Clinical Trial 
Network Center 
Indicator REF
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Table 11: Factors Associated with 9 Year Relative Hazard of Death Among HCT Patients by 
Distance/Match Categories, Cox Proportional Hazard models, Hazard Ratio, 95% CI   
  
Cox Model: Matched Unrelated Transplants by 
Distance Categories 2000-2009 
Cox Model: Mismatched Unrelated Transplants 
by Distance Categories 2000-2009 
  
Hazard 
Ratio 
95% CI P Value 
Hazard 
Ratio 
95% CI P Value 
Time Quartile Indicator 
Time Distance (2-32 min) REF REF 
Time Distance  (33-64 
min) 1.036 0.95 1.129 0.4222 1.026 0.912 1.155 0.6688 
Time Distance  (65-149 
min) 1.044 0.958 1.139 0.3266 1.046 0.924 1.184 0.4788 
Time Distance  (150-360 
min) 1.028 0.926 1.14 0.6086 0.91 0.785 1.055 0.2093 
Time Distance  (361-
20820 min) 1.072 0.952 1.208 0.2496 0.786 0.652 0.946 0.0111 
Transplant Year 
2000 REF REF 
2001 1.123 0.933 1.352 0.2196 0.888 0.743 1.061 0.191 
2002 1.01 0.849 1.2 0.914 0.885 0.731 1.072 0.2123 
2003 0.901 0.759 1.069 0.2308 0.776 0.648 0.93 0.0059 
2004 0.89 0.755 1.049 0.1656 0.721 0.601 0.865 0.0004 
2005 0.806 0.684 0.951 0.0104 0.563 0.466 0.68 <.0001 
2006 0.821 0.699 0.964 0.0163 0.69 0.572 0.831 <.0001 
2007 0.753 0.641 0.884 0.0005 0.647 0.537 0.78 <.0001 
2008 0.702 0.593 0.832 <.0001 0.565 0.464 0.689 <.0001 
2009 0.694 0.584 0.826 <.0001 0.592 0.48 0.73 <.0001 
Gender 
Male  REF REF 
Female 0.87 0.818 0.925 <.0001 0.954 0.874 1.04 0.2847 
Age Groups 
18 to 29 REF REF 
30 to 39 1.104 0.985 1.237 0.0899 1.117 0.966 1.291 0.1355 
40 to 49 1.265 1.138 1.407 <.0001 1.254 1.094 1.436 0.0011 
50 to 59 1.442 1.302 1.598 <.0001 1.369 1.19 1.575 <.0001 
60 to 64 1.593 1.407 1.802 <.0001 1.572 1.303 1.896 <.0001 
65+ 1.814 1.58 2.082 <.0001 1.244 0.975 1.588 0.0795 
Patient Race 
Non-Hispanic White  REF REF 
Hispanic  1.176 1.005 1.375 0.043 1.044 0.881 1.238 0.6163 
Black/African American 1.417 1.182 1.699 0.0002 1.142 0.959 1.359 0.1352 
Other/Multiple 
Race/Unknown 1.056 0.879 1.268 0.5603 1.053 0.847 1.308 0.6428 
Disease Group 
Acute Myelogenous 
Leukemia & 
Myelodysplastic 
Disorders  REF REF 
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Acute Lymphoblastic 
Leukemia 1.111 1.012 1.22 0.0274 1.188 1.051 1.343 0.006 
Other Leukemia & 
Myeloproliferative 
Syndromes 0.77 0.71 0.835 <.0001 0.991 0.886 1.108 0.8684 
Non-Hodgkin lymphoma 
(NHL) & Hodgkin 
Lymphoma (HL)  0.9 0.813 0.995 0.0391 0.989 0.835 1.172 0.9013 
Other Malignancy 1.332 1.028 1.726 0.0302 1.639 1.033 2.603 0.0361 
Severe Aplastic Anemia 0.51 0.4 0.649 <.0001 . . . . 
Other Non-Malignant 
Disease 0.927 0.587 1.463 0.744 . . . . 
Coexisting Disease 
Absent or Missing  REF REF 
Present 1.108 1.04 1.183 0.0021 1.158 1 1.271 0.0020 
Patient Karnofsky Performance Score 
90-100 REF REF 
≤80 0.715 1 0.764 <.0001 0.75 1 0.823 <.0001 
Missing  0.868 1 0.974 0.0157 0.852 1 1.017 0.0763 
Median Household Income Quartile Categories 
Quartile 1 ($10,055-
$43,796) REF REF 
Quartile 2 ($43,797-
$55,702) 0.881 0.81 0.96 0.0036 1.139 1.01 1.285 0.0343 
 Quartile 3 ($55,703-
$73,257) 0.915 0.84 0.999 0.0472 1.059 0.93 1.2 0.3705 
 Quartile 4 ($73,258-
$242,188) 0.864 0.79 0.948 0.0021 1.018 0.89 1.165 0.7996 
Missing  0.952 0.76 1.198 0.6757 0.984 0.71 1.373 0.9245 
FACT/Core Clinical Trial Network Center Indicator 
No FACT Affiliation 1.224 1.008 1.486 0.041 1.153 0.844 1.576 0.371 
FACT Only 1.152 1.065 1.245 0.0004 1.119 0.998 1.254 0.0543 
FACT/CTN REF REF 
Centers by Department of Health and Human Services Regions 
Region 1: (CT, ME, MA, 
NH, RI, & VT) REF REF 
Region 2: (NJ, NY)  1.077 0.918 1.264 0.36 0.999 0.804 1.24 0.9892 
Region 3: (DE, DC, MD, 
PA, VA, WV) 1.366 1.178 1.584 <.0001 1.44 1.175 1.766 0.0004 
Region 4: (AL, FL, GA, KY, 
MS, NC, SC, TN) 1.278 1.11 1.471 0.0006 1.092 0.889 1.341 0.4018 
Region 5: (IL, IN, MI, MN, 
OH, WI) 1.183 1.036 1.35 0.0129 1.047 0.871 1.259 0.6259 
Region 6: (AR, LA, NM, 
OK, TX) 1.127 0.981 1.295 0.0919 1.093 0.897 1.333 0.3774 
Region 7:(IA, KS, MO, NE)  1.263 1.069 1.493 0.0061 1.146 0.92 1.427 0.2236 
Region 8:(CO, MT, ND, 
SD, UT, WY)  1.155 0.926 1.439 0.2005 1.009 0.715 1.424 0.9596 
Region 9:(AZ, CA, HI, NV)  1.113 0.962 1.287 0.1518 1.001 0.818 1.224 0.9942 
Region 10 (AK, ID, OR, 
WA) 1.032 0.883 1.207 0.6908 1.063 0.845 1.338 0.6004 
Volume Quartile Indicator 
QI Centers (1-5 
Transplants) REF REF 
Q II Centers (6-44 
Transplants) 1.162 0.838 1.611 0.3674 0.998 0.674 1.478 0.9913 
Q III Centers (45-107 
Transplants)  1.153 0.841 1.583 0.3767 0.938 0.643 1.37 0.7421 
QIV Centers (108-713 
Transplants)  1.02 0.743 1.4 0.9011 0.878 0.602 1.281 0.5007 
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Table 12: Factors Associated with Odds of cGvHD Among HCT Patients by Distance Categories 
 
 
HLA Matched HLA Mismatched 
 
 
Odds 
Ratio 
95% CI Odds Ratio 95% CI 
Distance 
Indicator 
Below 6 Hour Driving Distance REF REF 
Above 6 Hours Driving Distance 0.91 0.78 1.07 1.55 1.19 2.01 
Transplant 
Year 
2000 REF REF 
2001 1.20 0.87 1.64 1.56 1.12 2.17 
2002 1.29 0.96 1.73 1.64 1.16 2.31 
2003 1.43 1.07 1.90 1.56 1.13 2.15 
2004 1.38 1.05 1.82 1.91 1.38 2.65 
2005 1.70 1.29 2.24 2.28 1.65 3.15 
2006 1.63 1.24 2.13 1.88 1.35 2.61 
2007 1.61 1.23 2.10 2.14 1.54 2.98 
2008 1.58 1.19 2.08 2.78 1.96 3.94 
2009 1.54 1.16 2.03 2.17 1.50 3.12 
Gender 
Male REF REF 
Female 0.92 0.83 1.01 1.05 0.90 1.21 
Patient Race 
Non-Hispanic White REF REF 
Hispanic 1.01 0.78 1.31 1.23 0.94 1.61 
Black/African American 0.76 0.55 1.04 0.64 0.47 0.87 
Other/Multiple Race/Unknown 1.18 0.88 1.58 1.09 0.77 1.53 
Recipient 
Age 
Category 
18-29 REF REF 
30-39 1.27 1.06 1.52 0.98 0.77 1.25 
40-49 1.12 0.94 1.32 1.03 0.82 1.29 
50-59 0.87 0.74 1.03 0.87 0.69 1.11 
60-69 0.87 0.71 1.06 0.70 0.51 0.98 
70-81+ 0.81 0.64 1.02 1.06 0.71 1.59 
Patient 
Karnofsky 
Performance 
Score 
90-100 REF REF 
≤80 1.52 1.36 1.70 1.52 1.29 1.79 
Missing 1.18 0.97 1.42 0.99 0.73 1.34 
Coexisting 
disease 
Absent REF REF 
Present 1.03 0.92 1.14 0.84 0.72 0.99 
Disease 
Group 
Acute Myelogenous Leukemia & 
Myelodysplastic Disorders 
REF REF 
Acute Lymphoblastic Leukemia 0.81 0.69 0.94 0.87 0.70 1.08 
Other Leukemia & 
Myeloproliferative Syndromes 1.36 1.19 1.55 1.21 1.00 1.47 
Non-Hodgkin lymphoma (NHL) 
& Hodgkin Lymphoma (HL) 
1.04 0.88 1.23 1.01 0.77 1.32 
Other Malignancy 1.51 0.92 2.46 0.64 0.31 1.33 
Severe Aplastic Anemia 0.77 0.57 1.05 1.05 0.68 1.61 
Other Non-Malignant Disease 0.64 0.32 1.29 0.32 0.13 0.83 
Median 
Household 
Income 
Quartile 
Categories 
Quartile 1 ($10,055-$43,796) REF REF 
Quartile 2 ($43,797-$55,702) 1.23 1.07 1.42 0.94 0.77 1.16 
Quartile 3 ($55,703-$73,257) 1.23 1.06 1.41 1.06 0.86 1.30 
Quartile 4 ($73,258-$242,188) 1.14 0.99 1.31 1.07 0.86 1.32 
Missing 0.98 0.67 1.43 1.04 0.59 1.86 
FACT/Core 
Clinical Trial 
Network 
Center 
Indicator 
No FACT Affiliation 1.17 0.84 1.61 0.98 0.59 1.64 
FACT Only 0.85 0.75 0.95 0.62 0.52 0.74 
FACT/CTN 
REF REF 
Volume 
Quartile 
Indicator 
QI Centers (1-5 Transplants) REF REF 
Q II Centers (6-44 Transplants) 1.34 0.79 2.27 1.56 0.76 3.23 
Q III Centers (45-107 
Transplants) 1.13 0.68 1.89 1.51 0.75 3.06 
QIV Centers (108-713 
Transplants) 2.02 1.21 3.37 2.01 0.99 4.06 
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Figure 8A: Unadjusted Kaplan Meier 9 Year Mortality Estimates for all Distance Categories 2000-2009 
 
 
 
 
 
 
 
 
 
 
 
 
Distance Category 5: Driving Distance ≥6 Hours 
Distance Category 1, 2, 3, 4: Driving Distance <6 
Hours 
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Figure 8B: Unadjusted Kaplan Meier 9 Year Mortality Estimates for all Distance Categories 2000-2009 (Survival >100 Days) 
 
 
 
 
 
 
 
 
 
 
Distance Category 5: Driving Distance >6 Hours 
Distance Category 1, 2, 3, 4: Driving Distance ≤6 
Hours 
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Figure 9A: Unadjusted Kaplan Meier 9 Year Mortality HCT Mismatched Estimates for all Distance 
Categories 2000-2009 
 
 
 
 
 
 
 
 
 
 
Distance Category 5: Driving Distance >6 Hours 
Distance Category 2: Driving Distance 65-149 min. 
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Figure 9B: Unadjusted Kaplan Meier 9 Year Mortality Estimates for Matched HCT by Distance 
Categories 2000-2009 
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Figure 10: Kaplan Meier Probability of cGvHD for Unrelated HCT by Distance Category  
 
  100 Days 365 Days 730 Days 1825 Days 
Distance Group 
1,2,3,4 
(≤360 Minutes) 
Number at Risk 8873 8363 5092 4753 4655 
∅ cGvHD 
Probability  93% 35% 27% 23% 
Distance Group 5 
(≥360 Minutes) 
Number at Risk 1023 838 533 501 490 
∅ cGvHD 
Probability  78% 34% 27% 23% 
 
 
Distance Category 5: Driving Distance >6 Hours 
Distance Category 1, 2, 3, 4: Driving Distance 2-6 hours 
Hours 
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Conclusion and Future Implications 
This 3-paper dissertation examined the relationship between several 
determinants of HCT survival. HCT care provides an important opportunity to identify 
how payers, providers and policymakers can achieve high quality outcomes in the 
context of accreditation, the management of patient case mix and distance to facility. 
Previous studies have identified that patient risk stratification in centers of excellence 
and patient distance to HCT centers are important factors in improved overall HCT 
outcomes. This research identified the current gaps in the knowledge surrounding the 
impact of high risk patient management, FACT and CTN accreditation, and distance on 
survival and outcomes.  
Overall, this research provides significant evidence for future guideline 
recommendations surrounding the relative impact of HCT risk management at high or 
low risk centers, FACT/CTN certified centers of excellence and HCT for long distance 
travelers. However, the exact mechanism behind identifying the best combined 
mechanisms for overall quality could significantly improve HCT care in the US and 
influence HCT providers’ abilities to achieve more favorable outcomes. Using data from 
the Center for International Blood & Marrow Transplant Research (CIBMTR), a registry 
that collects transplant essential data (TED) data that includes disease type, age, sex, 
pre-transplant disease stage, date of diagnosis, graft type and cause of death, this 
research evaluated the current gaps in knowledge by 1) Evaluating the mechanism 
between patient case mix and overall HCT center quality (survival)  2) Identifying if 
centers of excellence and accreditation could explain differences in outcomes overall 
center quality and patient outcomes for complex HCT 3) Understanding the impact of 
distance on overall survival and further evaluating the impact of distance on complex 
HLA mismatched patients. Overall, this research provides significant evidence for future 
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recommendations surrounding the relative impact of risk stratification, center 
accreditation and distance on HCT survival.  
Risk Stratification of Centers and HCT Quality  
Chapter 3 of this dissertation calls into question the notion that a transplant 
centers’ management of higher risk patients could impact and improve the survival of 
lower risk patients.  The number of HCTs increased dramatically over the last decade 
and novel clinical approaches have expanded HCT to a more complex case mix of 
patients. An increase in overall HCT risk will likely continue to be a more common trend 
in the coming decades. Nevertheless, the fact that HCT centers transplant higher risk 
patients does not imply that they are able to treat their lower risk patient population with 
improved quality. There is indeed no overwhelmingly advantageous “spillover” effect that 
occurs for the low risk HCT patient population as a result of having HCT in a center that 
treats patients with higher risk. The case mix of a center should not necessarily be 
viewed as a sign of excellence by payers, patients, providers, and HCT center 
administrators. From the payers’ perspective, HCT center case mix should not be a 
determinant of centers of excellence and low risk patient access should not be restricted 
to high risk centers. This might imply decreasing patient travel for lower risk HCT. 
Additionally, pay for performance initiatives should not simply reward high risk centers 
on the basis of case mix volume. For lower risk patients, our results can help guide their 
decision to transplant at a lower volume and lower risk centers and expect similar rates 
of survival. Finally, HCT center administrators and providers should not presume that 
augmenting higher risk patient volume case mix could improve overall outcomes for all 
patients, especially patients with lower risk. Combined these findings suggest that case 
mix cannot be a driving mechanism that maximizes HCT quality.     
Overall, these findings may bring insight to policy guidelines in other cancers. 
Future research should continue to evaluate the presumed mechanism of “learning by 
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doing” and examine how higher risk volume and patient management might improve 
outcomes in other cancers. For example, does high volume in higher risk patient 
population result in better outcomes for lower risk patients? Such studies might evaluate 
the relationship between the performance of treatment for higher risk patients and the 
resulting effect on overall outcomes for the entire patient population and particularly the 
lower risk patients. Other research might evaluate the types of centers that are most 
able to demonstrate high levels of quality with both low and high risk patients. These 
studies might also evaluate alternative mechanisms for evaluating the case mix of 
cancer centers. As healthcare resources are limited and persistent efforts to promote 
efficient, effective evidence based practice becomes widespread, these studies will 
become crucial for identifying guidelines that will likely have the largest impact on overall 
outcomes. Continued research in this area will further encourage effective use of 
healthcare resources, the promotion or effective risk management and the adoption of 
promising quality improvement strategies. 
Accredited Centers of Excellence and Quality Outcomes 
Chapter 4 further evaluates the mechanism between HCT risk and complexity 
and survival by examining whether this relationship could be partially explained by HCT 
center accreditation. This second study demonstrates that FACT/CTN centers are more 
adept at performing complex HLA mismatched HCT versus FACT-only and non-FACT 
accredited centers. These findings also illustrate the variation within the FACT category 
and also underscore the notion that FACT accreditation alone is not enough of an 
indicator to differentiate transplant centers. Although FACT/CTN centers consistently 
showed superior outcomes, for lower risk HLA matched patients, accreditation alone 
does not impact survival and does not appear to be the sole mechanism for improved 
survival. However, there were survival advantages in HCT at FACT-only centers versus 
non-FACT centers for more complex HCT mismatched patients. 
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These findings present two key opportunities of research. First, for nearly two 
decades, FACT accreditation has been acknowledged to be an accurate publicly 
available center indicator of excellence.  For example, FACT accreditation is a factor in 
the ranking of “America’s Best Hospitals,” and “America’s Best Children’s Hospitals,” 
published annually by U.S. News and World Report. These organizations presumably 
engage in a more transparent and open environment in which donor and cell selection 
standards are adhered to at the highest levels.  Although FACT status is an important 
standard that begins to define improved overall survival, our results indicate that FACT 
status alone is not an indicator of superior outcomes. Further research is needed to 
identify the components of quality that the FACT accreditation and publicly available 
guidelines have been able to disseminate to non-FACT centers. Additional research 
could identify specific factors that are implemented at FACT/CTN centers that could be 
introduced to all centers to improve outcomes. For example, additional analyses could 
find specific improvements implemented by early FACT adopters versus late adopting 
centers. Moreover, learning from the evolution of accredited centers over time will 
provide policy makers, administrators and payers with information to guide future 
resource planning and areas to focus future quality improvement efforts. 
Second, these findings bring scrutiny to the importance of accreditation. As 
evidenced by high levels of voluntary center FACT participation, accreditation has widely 
been viewed as an important gateway to ensure higher levels of quality. Further 
organizational research is needed to ascertain if the accreditation process is simply a fad 
or fashion in which HCT centers imitate the behavior of their counterparts through the 
accreditation process but experience no actual advantage in having FACT status. Other 
similar research might explore if the pressures to adopt accreditation policies and 
conforming to the market norms increases according to the number of other HCT 
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centers that have already adopted them and explore differences in early and late 
adopters of accreditation.  
The broader relationship between FACT status and a center’s specific HCT 
survival rate remains complex, requiring a deeper understanding of the causal 
mechanism involved and finding specific factors that could be disseminated to all centers 
to improve outcomes. Learning from the evolution of accredited centers over time will 
provide policy makers, administrators and payers with information to guide future 
resource planning and areas to focus future quality improvement efforts. This 
relationship should be examined in other cancers, particularly those that heavily rely on 
the accreditation process to support guideline and evidence based practice. 
Understanding how to identify those centers that adopt accreditation policy and 
simultaneously improve overall outcomes for all patients will be important for improving 
care and disseminating effective quality guidelines to all centers.  
Distance and HCT Outcomes 
Finally, chapter 5 examined distance to HCT centers and the impact on survival 
and post-transplant complications. Results showed that between 2001-2009 patients 
accessing HCT from longer distances could expect comparable survival and outcomes 
results compared to other patients. This was especially apparent for more complex 
patients. After adjusting for patient and center characteristics we observed a distinct 
significant advantage for more complex, HLA mismatched patients that traveled 
distances greater than 6 hours. These results suggest that HCT centers are able to 
ensure the success of transplants for patients who reside long distances from transplant 
centers perhaps by effectively disseminating advanced post-transplant care techniques 
to non-specialized clinicians providing post-transplant care. Additionally, our results 
imply that in addition to the precautions taken at the treatment center with long distance 
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patients there is additional caution taken for complex HCT that may include prolonged 
length of stay and resistance by both patient and provider to discharge too early.    
Overall, this research provides important insights into the potential implications 
for future research that explores the impact of distance and outcomes. Additionally, 
researchers should focus on identifying the most important early care components that 
most influence mortality and comorbidity within the HCT population. Further research 
with augmented datasets that include length of stay and post-transplant care variables 
could help determine the specific factors that should be introduced to all centers to 
improve outcomes for all long and short distance patients.  
In conclusion, understanding the mechanism that influences the relationship 
between complex HCT and improved center outcomes will be instrumental in the design 
of future quality improvement programs and the design and designation of centers of 
excellence. While center characteristics, HCT match quality, patient complexity, center 
case mix and travel distance for HCT are not the exclusive determinants of improved 
survival, identifying and understanding the best combined components that significantly 
improve cancer outcomes in the U.S. is imperative for the overall improvement of HCT 
care.  
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Appendix 1: Karnofsky Performance Score Table 
 
The CIBMTR uses Karnofsky/Lansky performance status to determine the functional 
status of a recipient. Recipient performance status is a critical data  field that has been 
determined to be essential for all outcome-based analyses. The Karnofsky Scale is 
designed for recipients aged 16 years and older. The Karnofsky score runs from 100 to 
0, where 100 is "perfect" health. The performance status is an attempt to quantify cancer 
patients' general well-being and activities of daily life and is used to measure of quality of 
life. CIBTMR categorizes the Karnofsky performance score as a dichotomous variable of 
90-100 (score of 0) and ≤ 80 (score of 1). 
 
Karnofsky Scale (recipient age ≥16 years) 
Able to carry on normal activity; no special care is needed 
100 Normal, no complaints, no evidence of disease 
90 Able to carry on normal activity 
80 Normal activity with effort 
Unable to work, able to live at home cares for most personal needs, a varying amount of 
assistance is needed 
70 
Cares for self, unable to carry on normal activity or to do active 
work 
60 Requires occasional assistance but is able to care for most needs 
50 Requires considerable assistance and frequent medical care 
Unable to care for self, requires equivalent of institutional or hospital care, disease may be 
progressing rapidly 
40 Disabled, requires special care and assistance 
30 
Severely disabled, hospitalization indicated, although death not 
imminent 
20 Very sick, hospitalization necessary 
10 Moribund, fatal process progressing rapidly 
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Appendix 2: Benefit of the Risk Category Stratification: Cox Proportional Hazard 
Models  
The following sensitivity analyses evaluate the benefit of creating a risk bundle versus 
testing each component (age, coexisting disease, human leukocyte antigen (HLA) match 
and Karnofsky score) of the risk bundle separately within our model. Utilizing cox 
proportional hazard models with and without our risk bundles we found no statistical 
benefit between the two models. Since they are nested models (one is a subset of the 
other) we tested whether the separate parameters significantly improve the fit using the -
2 Log Likelihood.  
 
The differences in the Log Likelihood (106913.38-106630.67=39.19) and is distributed 
as chi-square with 28 DF. This is a non-significant (p-value .1) indicating that including 
each component (age, coexisting disease, HLA match and Karnofsky score) of the risk 
category in the model does not lead to a better fir than the component risk category 
model. Although, the risk category model does not lead to a significantly better fit we 
found benefit to modeling the risk category variable in order to facilitate and simplify our 
center stratification. 
 
a) Model fit statistic with No Risk Category DF=28 
 
Model Fit Statistic 
Criterion  Without Covariates  With Covariates 
-2Log L 107277.67 106630.67 
AIC 107277.67 106686.67 
SBC 107277.67 106874.18 
 
b)        Model Fit Statistics with Risk Category DF=28 
 
Model Fit Statistic 
Criterion  Without Covariates  With Covariates 
-2Log L 107277.67 106630.67 
AIC 107277.67 106725.86 
SBC 107277.67 106913.38 
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Appendix 3: Inclusion of Related and Unrelated Donor for HSCT Risk Categories 
The following sensitivity analysis evaluates our consolidation of the related and 
unrelated donor HSCT groups within our risk categories.  We created independent risk 
categories composed of age, coexisting disease, human leukocyte antigen (HLA) match 
and Karnofsky-Lansky score for each type of donor, related and unrelated. Age, 
coexisting disease, and Karnofsky-Lansky score were categorized identically for both the 
related and unrelated transplant groups. For the HLA match status of donors we created 
separate categories for related and unrelated HSCT. For unrelated donors an 8/8 match 
was categorized as (1) and any mismatch (6/8, 7/8, partially matched, mismatched) were 
scored with a 0. For the related group a matched relative, matched sibling, synergenic 
donor was scored as 1and all others were scored as a 0.  
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Appendix 4: Existence of coexisting disease with the Calculated Risk Categories  
Due to the fact that CIBMTR broadly identifies coexisting disease and because patient 
inclusion within a risk category may be a construct of a center’s willingness to both over 
and under code the presence of coexisting disease, we tested our risk categories with 
and without the inclusion of co-existing disease in our models. Using Kaplan Meir curves 
we determined that our risk categories that included co-existing disease were no 
different from our Kaplan Meir cuvees that excluded coexisting disease.  
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Appendix 5: Risk Bundle Stratification with Hierarchical Linear Models   
The following sensitivity analysis evaluates the use of Hierarchical Linear Models (HLM) 
in opposition to cox proportional models. In our HLM risk categories defined patients are 
nested within our high and low risk centers. Below, we include the Odds Ratios of the 
HLM indicating that our conclusions are unchanged and that the use of HLM to verify 
that accounting for transplant recipients being nested in centers did not produce results 
of different magnitude or direction.  
 
Hierarchical Linear Model-All Centers 2008-2010 
    Odds Ratio 95% CI 
Risk Category Groups 0 REF 
 
1 1.877 1.596 2.208 
 
2 3.213 2.694 3.831 
 
3 5.116 3.916 6.684 
Gender 
Female REF 
Male  1.158 1.075 1.247 
Patient Race 
Non-Hispanic White 
 
REF 
Hispanic  1.07 0.925 1.236 
Black/African American 1.205 1.02 1.423 
Other/Multiple Race/Unknown 0.963 0.803 1.154 
Disease Group 
Acute Myelogenous Leukemia & Myelodysplastic Disorders  
REF 
Acute Lymphoblastic Leukemia 0.956 0.85 1.075 
Other Leukemia & Myeloproliferative Syndromes 0.668 0.598 0.747 
Non-Hodgkin lymphoma (NHL) & Hodgkin Lymphoma (HL)  
0.757 0.683 0.838 
Other Malignancy 0.938 0.784 1.122 
Severe Aplastic Anemia 0.404 0.313 0.522 
Other Non-Malignant Disease 0.499 0.315 0.79 
Centers by Department of 
Health and Human Services 
Regions 
Region 1: (CT, ME, MA, NH, RI, & VT) REF 
Region 2: (NJ, NY)  1.202 0.857 1.686 
Region 3: (DE, DC, MD, PA, VA, WV) 1.178 0.853 1.626 
Region 4: (AL, FL, GA, KY, MS, NC, SC, TN) 1072 0.791 1.452 
Region 5: (IL, IN, MI, MN, OH, WI) 0.966 0.712 1.31 
Region 6: (AR, LA, NM, OK, TX) 1.139 0.808 1.604 
Region 7:(IA, KS, MO, NE)  1.168 0.76 1.795 
Region 8:(CO, MT, ND, SD, UT, WY)  1.002 0.655 1.532 
Region 9:(AZ, CA, HI, NV)  1.016 0.734 1.408 
Region 10 (AK, ID, OR, WA) 0.867 0.547 1.375 
Center Characteristics 
Low Volume Indicator (2-54 Transplants)  REF 
High Volume Indicator (>=55 Transplants)  0.785 0.646 0.955 
Unrelated Donor Indicator REF 
Related Donor Indicator 0.843 0.781 0.909 
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Appendix 6: Cox Proportional Hazard Models with High Risk Category Exclusion 
The following sensitivity analysis evaluates the exclusion of our high risk category 
patients (RC=4) from our cox proportional hazard models for our high risk centers in 
order to verify that high risk patients do not drive our Hazard Ratio results for our lower 
risk patient population.  
Cox Model for High Risk Centers without High Risk Patients 2008-2010 
    Hazard Ratio 95% CI P Value 
Risk Category 
Groups 
0 REF 
1 1.635 1.405 1.903 <.0001 
2 2.465 2.108 2.882 <.0001 
Gender 
Male  REF 
Female 0.921 0.869 0.977 0.006 
Patient Race 
Caucasian  REF 
Hispanic  1.066 0.949 1.197 0.2831 
Black/African American 1.069 0.932 1.225 0.3397 
Other/Multiple Race/Unknown 0.97 0.838 1.122 0.6807 
Transplant 
Year 
2008 REF 
2009 0.978 0.912 1.049 0.5349 
2010 0.968 0.897 1.043 0.3914 
Disease Group 
Acute Myelogenous Leukemia & 
Myelodysplastic Disorders  
REF 
Acute Lymphoblastic Leukemia 
0.954 0.869 1.048 0.3287 
Other Leukemia & Myeloproliferative 
Syndromes 0.728 0.664 0.797 <.0001 
Non-Hodgkin lymphoma (NHL) & Hodgkin 
Lymphoma (HL)  
0.823 0.758 0.893 <.0001 
Other Malignancy 0.911 0.796 1.044 0.18 
Severe Aplastic Anemia 
0.608 0.481 0.768 <.0001 
Other Non-Malignant Disease 
0.71 0.44 1.148 0.1623 
Centers by 
Department of 
Health and 
Human 
Services 
Regions 
Region 1: (CT, ME, MA, NH, RI, & VT) REF 
Region 2: (NJ, NY)  1.14 0.996 1.304 0.0579 
Region 3: (DE, DC, MD, PA, VA, WV) 1.201 1.049 1.375 0.0079 
Region 4: (AL, FL, GA, KY, MS, NC, SC, TN) 1.158 1.025 1.309 0.0182 
Region 5: (IL, IN, MI, MN, OH, WI) 1.052 0.931 1.189 0.4134 
Region 6: (AR, LA, NM, OK, TX) 1.249 1.095 1.424 0.0009 
Region 7:(IA, KS, MO, NE)  1.312 1.128 1.526 0.0004 
Region 8:(CO, MT, ND, SD, UT, WY)  1.095 0.916 1.308 0.3199 
Region 9:(AZ, CA, HI, NV)  1.015 0.893 1.155 0.8155 
Region 10 (AK, ID, OR, WA) 1.035 0.893 1.199 0.6515 
Center 
Characteristics 
High Volume Indicator (>=55 Transplants)  1.378 1.203 1.578 <.0001 
Related Donor Indicator 1.156 1.089 1.227 <.0001 
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Appendix 7: Separate Kaplan Meir curves for Risk by Age (>40 versus ≤40), 
Coexisting Disease (Present versus Absent), Karnofsky Performance Score (>90 
versus ≤80) and HLA Match (Match versus Mismatch)   
In order to ensure that our defined risk of >40, coexisting disease, Karnofsky score <90 
and HLA mismatch were accurate representations of risk we tested each component of 
our risk categories separately using Kaplan Meir curves. Below, the set of Kaplan Meir 
curves indicates that our risk components are verified measures of risk.  
 
 
 
 
 
 130 
 
 
 
 131 
 
 
 132 
 
 
 
 
 
 
 
 
 
 
 133 
 
Appendix 8: Separate Kaplan Meir curves for Sorror Score versus Coexisting 
Disease 
While we acknowledge that the HCT comorbidity index (CI) and the sorror comorbidity 
score are more accurate representations of patient comorbidities, the variable was 
underreported by centers relative to patient co-existing disease. 18 Nevertheless, we 
conducted sensitivity analyses utilizing the sorror comorbidity score that did not produce 
results of different magnitude or direction for our overall risk categories. Median Survival 
in Days for Sorror risk group =478 days 35% survival at 1080 days while the Median 
Survival in Days for Coexisting Disease=595 Days. 46% survival at 1080 days. 
Nevertheless, when we plot KM curves for our overall risk categories results are 
unchanged.  
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Appendix 9: Correlation of Risk Category Components 
The following sensitivity analysis evaluates our consolidation of the risk components 
using Spearman correlation. Results indicate that our risk components are not highly 
correlated and independently measure risk.  
  Median for All Centers 
Coexexting Disease Risk Percentage (Present) 60.2 
Karnofsky Score Risk Percentage (<90) 25.0 
Age Risk Category Risk Percentage (Age>40) 13.7 
HLA Mismatch Risk Percentage (Mismatched HCT) 73.9 
 
 
Spearman Correlation Coefficients, N = 162 
  
Coexisting 
Disease 
Percentage  
Karnofsky 
Score 
Percentage  
Age Risk 
Category 
Percentage 
HLA Mismatch 
Percentage 
Coexisting Disease 
Percentage  1       
Karnofsky Score 
Percentage  0.24 (.002) 1     
Age Risk Category 
Percentage -.06(.42) 0.16 (.04) 1   
HLA Mismatch 
Percentage 0.16 (.05) 
0.32 
(<.0001) -0.01 (.93) 1 
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Appendix 10: FACT/CTN status for High and Low Risk Centers 
In order to verify our Chapter 4 FACT/CTN status differences on Chapter 3 findings (High Risk 
Low Risk Centers). We found that high risk centers were also most likely to have FACT/CTN 
status. Additionally, when using our Chapter 3 Cox Models with FACT/CTN status we found our 
risk category findings unchanged.  
 
 
 
 
 
 
 
 
 
Cox Model for All Centers (High and Low Risk Centers) with FACT/CTN Status 2008-2010 
    
Hazard 
Ratio 
95% CI P Value 
Risk 
Categories  
0 REF 
1/2 1.719 1.508 1.959 <.0001 
3 2.543 2.219 2.914 <.0001 
4 3.360 2.823 3.999 <.0001 
Gender 
Male  REF 
Female 0.914 0.867 0.962 0.0006 
Patient Race 
Non-Hispanic White REF 
Hispanic  1.051 0.950 1.162 0.3350 
Black/African 
American 
1.168 1.045 1.305 
0.0062 
Other/Multiple 
Race/Unknown 
1.001 0.878 1.141 
0.9938 
Transplant 
Year 
2008 REF 
2009 1.005 0.944 1.069 0.8831 
2010 1.010 0.944 1.079 0.7792 
Disease 
Group 
Acute Myelogenous 
Leukemia & 
Myelodysplastic 
Disorders  
REF 
Acute Lymphoblastic 
Leukemia 0.986 0.908 1.070 0.7288 
Other Leukemia & 
Myeloproliferative 
Syndromes 0.763 0.703 0.827 <.0001 
Non-Hodgkin 
lymphoma (NHL) & 
Hodgkin Lymphoma 
(HL)  0.835 0.776 0.898 <.0001 
Other Malignancy 0.926 0.819 1.047 0.2173 
Severe Aplastic 
Anemia 0.553 0.449 0.681 <.0001 
Other Non-
Malignant Disease 0.649 0.452 0.933 0.0195 
  Low Risk Centers (73 Centers) High Risk Centers (74 Centers) 
FACT Status N (%) N (%) 
Non-FACT Center (16 Centers) 10 (63) 6 (37) 
FACT Only Center (99 Centers) 57 (56) 42 (44) 
FACT/CTN Center (32 Centers) 6 (19) 26 (81) 
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Cox Model ALL  
 
    
Hazard 
Ratio 
95% CI P Value 
Centers by 
Department 
of Health and 
Human 
Services 
Regions 
Region 1: (CT, ME, 
MA, NH, RI, & VT) 
REF 
Region 2: (NJ, NY)  1.075 0.948 1.219 0.2581 
Region 3: (DE, DC, 
MD, PA, VA, WV) 
1.149 1.017 1.297 
0.0254 
Region 4: (AL, FL, 
GA, KY, MS, NC, SC, 
TN) 
1.107 0.990 1.238 
0.0746 
Region 5: (IL, IN, MI, 
MN, OH, WI) 
1.010 0.902 1.131 
0.8626 
Region 6: (AR, LA, 
NM, OK, TX) 
1.140 1.010 1.286 
0.0335 
Region 7:(IA, KS, 
MO, NE)  
1.306 1.134 1.505 
0.0002 
Region 8:(CO, MT, 
ND, SD, UT, WY)  
1.022 0.858 1.218 
0.8059 
Region 9:(AZ, CA, HI, 
NV)  
1.042 0.925 1.174 
0.4946 
Region 10 (AK, ID, 
OR, WA) 
1.103 0.956 1.272 
0.1783 
Center 
Characteristic
s 
Low Volume 
Indicator (≤55 
Transplants)  
REF 
High Volume 
Indicator (>55 
Transplants)  
1.127 1.025 1.239 
0.0131 
Related Donor 
Indictor 
REF 
Unrelated Donor 
Indicator 
1.155 1.096 1.218 
<.0001 
Non-FACT  REF 
FACT Only 1.028 0.904 1.170 0.6714 
FACT/CTN .841 .736 .961 0.0111 
Low Risk Center 
Indicator 
REF 
High Risk Center 
Indicator 
1.079 0.994 1.170 
0.0681 
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Appendix 11: Benefit of including Volume Quartiles for the Relative Odds of HLA Mismatch 
among Related and Unrelated Transplant recipients 
The following sensitivity analyses evaluate the benefit of including volume in our models. 
Utilizing Logistic regression with and without volume we found statistical benefit between 
the two models. Since these are nested models (one is a subset of the other) we can 
test whether the separate parameters significantly improve the fit using the -2 Log 
Likelihood.   
The difference in the Log Likelihood is (3042.038-3054.511=12.481) and is distributed 
as chi-square with 3 DF. This is a significant (p-value <.01), indicating that including the 
volume quartiles in the model does lead to a better fit compared to the model that does 
not include volume.  
 
a) Model fit statistic with no volume indicator (31 DF) 
 
 
Model Fit Statistics 
Criterion Intercept 
Only 
Intercept 
and 
Covariates 
AIC 3767.272 3118.511 
SC 3773.970 3332.837 
-2 Log L 3765.272 3054.511 
 
 
 
 
b) Model fit statistics with a volume indicator (34 DF) 
 
 
Model Fit Statistics 
Criterion Intercept 
Only 
Intercept 
and 
Covariates 
AIC 3767.272 3112.038 
SC 3773.970 3346.456 
-2 Log L 3765.272 3042.038 
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Appendix 12: High Volume Centers by FACT/CTN Status 
In order to ensure that our FACT/CTN findings were only a product of low HCT volume 
settings we tested FACT/CTN status using Kaplan Meir curves. Below, the set of Kaplan 
Meir curves indicates that our high volume centers show the same trends illustrated by 
our overall results. Namely, FACT/CTN centers show superior survival probability than 
FACT-only and non-FACT status centers.   
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Appendix 13A-13E: FACT/CTN Status by HLA Related and Unrelated Group by 
FACT Status 
In order to justify our consolidation of (a) related and unrelated matched and (b) related 
and unrelated mismatched we conducted separate analyses for each individual group 
using Kaplan Meir curves and cox proportional models. Our results did not produce 
results of different magnitude or direction.  
 
 
FACT/CTN Status Matched Unrelated  
FACT Only Status Matched Unrelated  
Non-FACT Matched 
Unrelated 
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FACT/CTN Status Matched Related  
FACT Only Status Matched Related 
Non-FACT Status Matched Related  
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Non-FACT Status Mismatched Related  
FACT/CTN Status Mismatched Related 
FACT Only Status Mismatched Related 
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Non-FACT Status Mismatched Unrelated 
FACT Only Status Mismatched Unrelated 
FACT/CTN Status Mismatched Unrelated 
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Appendix 14: Inclusion of various time Distance cut-offs 
A recent study by Abou-Nassar, et al. analyzed a cohort of adult patients who underwent 
allogeneic HCT at the Dana-Farber/Brigham and Women’s Cancer Center between 
1996 and 2009 and who resided within 6 hours driving time of the institution.3 Although 
Abou-Nassar et al. established 6 hour driving distance as a potential impactful distance 
on HCT outcomes we tested other times to ensure that our results were not a product of 
an arbitrary cut-off. Results from our Kaplan Meier curves for our quartiles (without 
dividing the upper quartile), >5 hours, >7 hours all showed similar survival trends. 
Namely, longer driving distances showed superior results.  
 
 
Driving Distance ≥7 Hours  
Driving Distance < 7 Hours  
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Driving Distance ≥5Hours  
Driving Distance < 5 Hours  
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Upper Quartile (>150 Minutes)  
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Appendix 15: HLA Matched and Mismatched 100 Day cut-off 
Length of stay (LOS) and 100 day survival has typically been used by literature as an 
important cutoff for HCT and survival outcomes. Although CIBTMR does not collect LOS 
from transplant centers we used 100 day survival as a proxy for LOS to determine if the 
difference in survival probability for HLA matched and mismatched HCT by distance 
category persisted and if long distance complex patients did indeed have superior OS 
results compared to equally complex HLA mismatched HCT patients that lived in close 
proximity to HCT centers. Our sensitivity analysis indicated a similar trend relative to our 
initial findings that complex long distance patients see an OS advantage versus other 
HLA mismatched HCT patients. Conversely, the trend for HLA matched patients, in 
which no distinction was observed by distance, also persisted.  
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Appendix 16: Length of Stay (LOS) Proxy and Inclusion of Various Time Distances Cut-
Offs 
In order to ensure that our choice of 100 days was not an arbitrary proxy for LOS we 
used a series of survival cut-offs for LOS including, 30 days, 60 days, 90 days, 100 
days, 120 days. Our Kaplan Meier curves did not produce results of different magnitude 
or direction.  
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Distance Quartiles: Survival >30 Days 
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Distance Quartiles: Survival >60 Days 
 
 153 
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Distance Quartiles: Survival >90 Days 
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Distance Quartiles: Survival >100 Days 
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Distance Quartiles: Survival >120 Days 
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Appendix 17: Use of aGvHD to Confirm Distance Findings   
aGvHD is commonly attributed to HLA mismatch. While aGvHD is an imporatnat 
outcome for HCT pateints our sample did not provide sufficient N to measure differences 
in aGvHD by distance categories.  
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Appendix 18: Use of cGvHD to Confirm Distance Findings for HLA Mismatched 
Patinets  
cGvHD is commonly attributed to HLA mismatch. In order to ensure that our distance 
trends that illustrated that the unadjusted probablity of cGvHD was less commmon for 
pateints travelling >6 hours for HCT, we used Kaplan Meier curves for driving distance 
by HLA match/mismateched status. As the risk of cGvHD tails off after 2 years we used 
730 days as the end of our observation period. Below we include Kaplan Meier curves 
for both the 730 days and the full 9 year observation period. Our sensitvity analysis 
inicated that the unadjusted probablity of cGvHD was less commmon for both HLA 
matcehd/mismatched pateints travelling >6 hours for HCT.     
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Appendix 19:  Disease specific (AML MDS and ALL) Distance Results 
In order to ensure that disease categories were not driving our distance results we 
prefromed a subset anlysis of 3 major diease categoreis, AML, MDS and ALL. Our 
Kaplan Meier curves did not produce results of different magnitude or direction.  
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